



Medical Coverage Policy

Effective Date7/15/2024

Next Review Date6/15/2025

Coverage Policy Number..... 0453

Inhaled Nitric Oxide (INO)

Table of Contents

Overview 2
 Coverage Policy..... 2
 Health Equity Considerations..... 2
 General Background 2
 Medicare Coverage Determinations 26
 Coding Information..... 26
 References 27
 Revision Details 41

Related Coverage Resources

- [Exhaled Nitric Oxide in the Management of Respiratory Disorders](#)
- [Heart, Lung, and Heart-Lung Transplantation Ventricular Assist Devices \(VADs\), Percutaneous Cardiac Support Systems and Total Artificial Heart](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see “Coding Information” below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy

will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses the use of inhaled nitric oxide (INO), a minimally invasive therapy, proposed for the treatment of conditions associated with reversible pulmonary vasoconstriction and pulmonary hypertension in children and adults.

Coverage Policy

Inhaled nitric oxide is considered medically necessary for ANY of the following indications:

- hypoxic respiratory failure in a term or near-term infant (i.e., born at more than 34 weeks gestation) in the absence of congenital diaphragmatic hernia when there is failure, contraindication or intolerance to conventional therapy (e.g., high concentrations of oxygen, hyperventilation, sedation)
- postoperative management of pulmonary hypertension following repair of congenital heart disease
- postoperative management of pulmonary hypertensive crisis following pediatric heart or lung surgery
- pulmonary hypertension during heart catheterization to determine pulmonary vasoreactivity

Inhaled nitric oxide for any other indication, including but not limited to acute respiratory distress syndrome and adult heart and/or lung transplantation, is considered not medically necessary due to insufficient evidence of safety and efficacy.

Health Equity Considerations

Health equity is the highest level of health for all people; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which people are born, grow, live, work, and age.

Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include safe housing, transportation and neighborhoods; racism, discrimination and violence; education, job opportunities and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

General Background

Nitric oxide (NO) is a compound naturally produced in numerous cells in the body and is involved in many physiologic functions, such as neurotransmission and vascular tone. It is found in neurons, macrophages, and in the endothelial and smooth muscle cells in the lining of the lumen of blood vessels. As the endothelial cells within the blood vessels release NO, the vessels relax and dilate, enhancing blood flow (Klinger, 2022).

NO is commercially available as a colorless, nonflammable, almost odorless gas used for therapeutic administration by inhalation (i.e., inhaled nitric oxide). Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has been proposed for the treatment of conditions associated with reversible vasoconstriction and pulmonary hypertension. The administration of INO is a minimally invasive treatment typically involving the inhalation of NO in conjunction with ventilatory support. Absorbed systemically after inhalation, NO combines with hemoglobin and enters the circulation as methemoglobin and nitrate. INO vasodilates only those areas that are ventilated and results in improvement of perfusion and oxygenation. Nitric oxide, unstable in air, undergoes spontaneous oxidation to nitrogen dioxide (NO₂). NO₂ is known to be directly toxic to the respiratory tract. Due to this instability and potential toxicity, continuous, in-line monitoring of the administration of INO is the standard of care during therapeutic administration (Stark and Eichenwald, 2023; Ryan and Tobias, 2007; Griffiths and Evans, 2005). Inhaled NO is contraindicated in neonates dependent on right-to-left shunting of blood (i.e., patent ductus arteriosus [PDA]-dependent congenital heart disease).

U.S. Food and Drug Administration (FDA)

A complete nitric oxide delivery system is comprised of a nitric oxide administration apparatus, a nitric oxide gas analyzer, and a nitrogen dioxide gas analyzer. The first FDA-approved commercially available nitric oxide product was INOmax[®] (INO Therapeutics Inc.). INOmax is a gaseous blend of nitric oxide (0.08%) and nitrogen (99.92%), and is supplied in aluminum cylinders as a compressed gas under high pressure.

INOmax, in conjunction with ventilatory support and other appropriate agents (e.g., surfactant), is approved by the FDA "for the treatment of term and near-term (i.e., > 34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation". PaO₂, methemoglobin, and inspired NO₂ should be monitored during INOmax administration. The apparatuses for administration of INO are regulated by the FDA as Class II devices. An example of a delivery device is the INOvent (Ohmeda Medical, Laurel, MD). FDA-approved therapeutic equivalents for INOmax include Noxivent[®] (Linde AG, Danbury, CT; 2018) and ULSPIRA[™] (Airgas Therapeutics, Radnor, PA; 2023).

The "Clinical Studies" section of the FDA-approved INOmax labeling notes the following (FDA, 2023):

- "In clinical trials, reduction in the need for ECMO has not been demonstrated with the use of inhaled nitric oxide in neonates with congenital diaphragmatic hernia (CDH)."
- "INOmax is not indicated for use in ARDS."
- "The use of INOmax for prevention of BPD in preterm neonates ≤ 34 weeks gestational age is not recommended."

In 2019, the FDA approved the new drug application (NDA) for Genosyl[®] (Vero Biotech, Atlanta, GA), as an inhaled nitric oxide "to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension." Genosyl must be administered using a calibrated, tankless Genosyl delivery system (DS). In 2021, a Class I recall was issued for over 400 Genosyl DS nitric oxide (NO) delivery systems due to a software issue that led to errors in the delivery of NO. The issue caused delivery of lower-than-expected dosage of NO during the transition between the primary and backup console. A software update was released to repair the issue.

In June 2022, the FDA approved the LungFit® PH nitric oxide generator and delivery system (Beyond Air, Inc., Garden City, NY). The device generates nitric oxide from room air, without the use of cylinders. The approved indication for the LungFit PH device is the same as for other nitric oxide products, that is, "to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents." The device is contraindicated in neonates dependent on right-to-left shunting of blood.

Hypoxic Respiratory Failure

A primary clinical indication for INO, in conjunction with ventilatory support and other treatment modalities (e.g., surfactant), is hypoxic respiratory failure secondary to pulmonary hypertension in neonates born at more than 34 weeks gestation. Persistent pulmonary hypertension of the newborn (PPHN) may occur as a primary developmental defect or as a condition secondary to morbidities such as respiratory distress syndrome (i.e., hyaline membrane disease), meconium aspiration syndrome, pneumonia, sepsis, congenital diaphragmatic hernia, cardiac malformations and pulmonary hypoplasia (Sprecher, et al., 2025; American Academy of Pediatrics [AAP] 2014; Weinberger, et al., 2001). PPHN is characterized by the sustained elevation of pulmonary vascular resistance and severe hypoxemia secondary to extrapulmonary shunting of deoxygenated blood right-to-left across the patent ductus arteriosus and patent foramen ovale (Mandell, et al., 2020). Among neonates, Black children have a higher prevalence of PPHN and an increased mortality risk, while a lower risk of PPHN has been observed among white children (Ong, et al., 2019).

The goal of therapy for PPHN is to maximize the amount of oxygen transported by the lungs and, in turn, to systemic circulation. Conventional therapies include high concentrations of oxygen, hyperventilation, high-frequency ventilation, induction of alkalosis, neuromuscular blockade, and sedation. When conventional therapies fail, INO may be indicated. INO improves oxygenation, decreases the need for extracorporeal membrane oxygenation (ECMO), and decreases mortality. In addition to pulmonary vasodilatation and a reduction in extrapulmonary right-to-left shunting, INO also improves ventilation/perfusion matching, decreases lung inflammation, and enhances growth in the immature lung (Kinsella, 2006; Walsh-Sukys, et al., 2000).

The recommended initial dose of INO is 20 parts per million (ppm). Studies have included treatment with 5–80 ppm of INO. Toxicity is typically seen in doses \geq 80 ppm; however, the occurrence of toxicity has also been seen at lower doses. The duration of therapy is normally less than five days, but may be maintained for up to 14 days, or until the underlying oxygen desaturation has been resolved, and the neonate is ready to be weaned from therapy. To avoid rebound vasospasm, the infant is slowly weaned off of INO. Abrupt withdrawal of INO may lead to worsening oxygenation and increased pulmonary artery pressure. According to the AAP, INO is indicated when ventilatory therapy has failed, and ECMO is usually initiated only after INO fails due to the significant morbidity and mortality rates associated with ECMO. Because hypoxic respiratory failure often progresses rapidly, it is suggested that ECMO be available at facilities that have INO. If the infant must be transferred for ECMO, INO should not be discontinued (Sprecher, et al., 2025; FDA, 2023; Hintz, et al., 2000; Walsh-Sukys, et al., 2000).

Studies have demonstrated that INO is ineffective or has minimal effect in newborns with congenital diaphragmatic hernia, even when INO treatment was combined with surfactant. The cause of hypoxic respiratory failure in these infants is complex and includes pulmonary hypoplasia, surfactant dysfunction, functional and structural abnormalities of the pulmonary vascular bed, and left ventricular dysfunction. Response is low due to the possible combination of lung hypoplasia and immaturity, and PPHN aggravated by left ventricular underdevelopment. Some infants with congenital diaphragmatic hernia have prolonged pulmonary hypertension despite improvements in pulmonary function and gas exchange. The incidence of death or requiring ECMO for newborns

with congenital diaphragmatic hernias was not statistically different in infants who received INO compared to infants who did not receive INO. The lack of efficacy of INO has been attributed to the complexity of the disease. INO has not been proven to be beneficial in the treatment of hypoxic respiratory failure in the infant less than birth age 34 weeks gestation, with congenital diaphragmatic hernia, or in the treatment of acute respiratory distress syndrome.

Literature Review: Systematic reviews, meta-analyses, randomized controlled trials, and case series have reported that INO improved systemic oxygenation and that fewer term and near-term infants with birth age greater than 34 weeks gestation required ECMO and/or developed chronic lung disease. Some studies reported a higher survival rate following INO therapy. Studies consistently demonstrated the ineffectiveness of INO when used in the treatment of infants with congenital diaphragmatic hernia (CDH) (Wang, et al., 2019; Barrington, et al., 2017a; Putnam, et al., 2016; Wang, et al., 2011; Rosenberg, et al., 2010; Hoskote, et al., 2008; Field, et al., 2007; Kinsella, 2006; Kinsella and Abman, 2005; Konduri, et al., 2004; Clark, et al., 2000; Oliveira, et al., 2000; Weinberger, et al., 2001; Neonatal Inhaled Nitric Oxide Study Group, 1997).

Postoperative Management of Pulmonary Hypertension with Congenital Heart Disease (CHD)

Depending on the severity of the disease, CHD can increase pulmonary blood flow or cause pulmonary venous obstruction, leading to pulmonary artery smooth muscle hypertrophy, vasoconstriction, vascular obliteration and pulmonary hypertension. At that point, surgical intervention may be indicated to reverse the condition and ward off impending death. Following surgical intervention, children and adults can experience life-threatening reactive or persistent elevated pulmonary arterial pressure, or pulmonary hypertension. Due to its specificity for the pulmonary vascular bed, INO acts directly on pulmonary vascular smooth muscle. It is inactivated when exposed to hemoglobin, therefore avoiding side effects of systemic vasodilation that may be encountered with the use of other available vasodilators. Alternatives to the use of INO include ECMO and ventricular assist devices. Because of its ability to decrease pulmonary vascular resistance (PVR) and intrapulmonary shunting, and to increase oxygenation, INO is an established treatment option for pulmonary hypertension following surgical repair of congenital heart disease.

Literature Review: Randomized controlled trials, non-randomized comparative studies, and case series have reported that INO effectively lowered pulmonary vascular resistance and pulmonary artery pressure in children and adults with pulmonary hypertension after open heart surgery. However, it did not appear to increase the survival rate in those with severe pulmonary hypertension (Bizzarro, et al., 2014; Carroll, et al., 2005; Ichinose, et al., 2004; Kawakami and Ichinose, 2004; Hermon, et al., 2003; Sharma, et al., 2001; Miller, et al., 2000; Morris, et al., 2000).

Postoperative Management of Pulmonary Hypertensive Crisis (PHC) Following Pediatric Heart or Lung Surgery

According to the 2015 American Heart Association (AHA) and American Thoracic Society (ATS) pediatric guidelines on the treatment of pulmonary hypertension, studies of pathophysiology and management of acute PHCs have been in the critical care setting primarily focused on the perioperative period after cardiac and lung surgery. PHC is sudden, potentially lethal, and can be triggered by various stimuli (e.g., pain, anxiety, tracheal suction, hypoxia, acidosis). The diagnosis of postoperative PHC may include a sudden increase in pulmonary artery pressure, followed by an increase in right atrial and right ventricular end-diastolic pressures, decreased systemic and mixed venous oxygen saturations, decreased systemic pressure, and decreased cardiac output. Bronchoconstriction or increased airway resistance may accompany these hemodynamic changes. PHC can prolong hospitalization and the need for mechanical ventilation. It can also increase postoperative mortality. Respiratory management plays a critical role in the treatment of pulmonary hypertension and avoidance of PHCs. Although there are a limited number of well-

designed published studies on the outcomes of INO for the treatment of postoperative management of PHC following pediatric heart or lung surgery, INO is an established treatment option for this subpopulation. The AHA/ATS guideline made a class I, level B recommendation (i.e., the treatment should be performed and is effective) for the use of INO as an initial adjunctive therapy with conventional postoperative care for this subpopulation of children (Abman, et al., 2015).

Diagnostic Testing for Pulmonary Hypertension

The initial evaluation for the diagnosis of pulmonary hypertension in adults and children may include conventional therapies, such as chest radiography, electrocardiogram, echocardiogram, Doppler echocardiography, pulmonary function studies, and arterial blood gases. If the pulmonary hypertension cannot be confirmed by these conventional diagnostic studies, a right-heart catheterization using a pulmonary vasodilator may be indicated. INO may be administered as a vasodilator to assess pulmonary vasoreactivity in the management of pulmonary hypertension. A positive response to a vasodilating agent is indicative of favorable long-term clinical outcomes. A decrease in pulmonary artery pressure or pulmonary vascular resistance (PVR) in response to INO predicts a subsequent beneficial response to oral vasodilators such as nifedipine and identifies candidates who will benefit from long-term calcium channel blockers. INO testing can also help to determine if a patient is a good surgical candidate. Intravenous prostacyclin, adenosine and channel blockers may also be used to assess pulmonary vasoreactivity. Proponents of INO state that due to the potent, short-acting vasodilatory effect of INO and the possibility of severe hypotension, increased intrapulmonary right-to-left shunting and death in response to other agents, INO is considered a safer alternative. INO is an established vasodilator for diagnostic testing for pulmonary hypertension (Park and Salamat, 2021; Krasuski, et al., 2011; Bloch, et al., 2007; Minai and Budev, 2007; Ichinose, et al., 2004).

Literature Review: Randomized controlled trials, case series and nonrandomized comparative studies have reported a significant decrease in systemic and pulmonary vascular resistance and mean pulmonary artery pressure, as well as an increase in cardiac output following INO therapy. The administration of INO with oxygen compared to oxygen alone resulted in more accurate selection of surgical candidates. When oxygen alone was compared to oxygen/INO administration, accuracy (68% vs. 90%, respectively) and sensitivity (64% vs. 97%, respectively) were increased with INO administration when the systemic vascular resistance index:systemic vascular resistance index (Rp:Rs) <0.33 was used as the criterion for operability (Barst, et al., 2010; Cannon, et al., 2005; Leuchte, et al., 2004).

Other Proposed Indications

Due to INO's success in treating persistent pulmonary hypertension (PPHN) in term and near-term neonates and the postoperative management of pulmonary hypertension following repair of congenital heart disease, INO has been proposed for the treatment of other conditions, including: respiratory distress in preterm infants less than birth age 34 weeks gestation; chronic lung disease or bronchopulmonary dysplasia in preterm infants; acute respiratory failure in older children and adults; adult heart and lung transplantation; chronic obstructive pulmonary disease in adults; pulmonary vascular resistance following ventricular assist device insertion; sickle cell disease; chronic pulmonary hypertension; cardiogenic shock; pain associated with coronary artery disease; and other conditions associated with pulmonary hypertension. There is insufficient evidence in the published peer-reviewed scientific literature to support the safety and efficacy of INO for all other indications. Selection criteria for patients who will benefit from INO, dosage and duration of therapy, beneficial clinical outcomes, and long-term outcomes have not been established (Tavare and Tsakok, 2011; Arul and Konduri, 2009).

Respiratory Distress in Preterm Infants less than Birth Age 34 Weeks Gestation: Early studies demonstrated acute improvement in oxygenation in preterm infants with severe hypoxic

respiratory failure treated with INO, however survival was not improved, and there was a high rate of intracranial bleeding. Studies for the administration of INO in premature infants less than birth age 34 weeks gestation with respiratory distress of various etiologies including bronchopulmonary dysplasia (BPD) are ongoing and inconclusive. Collectively, the results of the studies indicated that INO has not been proven beneficial for the treatment of this subpopulation. The long-term pulmonary and extrapulmonary effects (e.g., pulmonary cell proliferation and differentiation, alveolar and microvascular development) of INO have not been reported. Standard care in preterm infants with respiratory distress syndrome (RDS) may include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure, and oxygen therapy (Martin, 2024; National Heart, Lung, and Blood Institute [NHLBI], 2022).

Particular interest has been paid to INO treatment in preterm infants with persistent pulmonary hypertension of the newborn (PPHN), and its use in this subset of patients persists contrary to clinical evidence, FDA labeling, and expert opinion. Although INO improves oxygenation in term and near-term infants with PPHN, trials in preterm infants have, as a whole, not demonstrated improved mortality or outcomes. The evidence is primarily in the form of case series with small patient populations, and studies are often limited by confounding factors (e.g., baseline patient characteristics, timing of treatment), and conflicting outcomes. Within the context of some larger trials of INO in preterm infants, subanalyses of neonates with PPHN have not demonstrated improved survival with INO therapy. Presently, there is insufficient evidence in the published literature to support the use of INO in preterm infants with PPHN (Marks and Schreiber, 2023; Stark and Eichenwald, 2023; Lakshminrusimha and Keszler, 2022; Carey, et al., 2018; Ellsworth, et al., 2018; Soll, 2018; Hasan, et al., 2017; American Academy of Pediatrics [AAP], 2014; Aikio, et al., 2012; Chock, et al., 2009).

Literature Review: Chandrasekharan et al. (2020) conducted a study to evaluate the survival and neurodevelopmental impairment (NDI) in extremely low birth weight (ELBW) infants at 18 to 26 months with early hypoxemic respiratory failure (HRF) and to assess whether African American infants with early HRF had improved outcomes after exposure to inhaled nitric oxide (INO). The study included retrospective analysis, and also included prospectively collected individual patient data from an established neonatal research network of academic institutions. The study included ELBW infants ≤ 1000 g and gestational age ≤ 26 weeks with maximal oxygen $\geq 60\%$ on either day one or day three that were labeled as "early HRF" and born between 2007 and 2015 in the Neonatal Research Network. Using a propensity score regression model, outcomes and effects of exposure to INO overall and separately by race were analyzed. Among 7,639 ELBW infants born ≤ 26 weeks, 22.7% had early HRF. Early HRF was associated with a mortality of 51.3%. The incidence of moderate-severe NDI among survivors was 41.2% at 18 to 26 months. Mortality among infants treated with INO was 59.4%. Female sex (adjusted odds ratio [aOR]: 2.4, 95% confidence interval [CI]: 1.8-3.3), birth weight ≥ 720 g (aOR: 2.3, 95% CI: 1.7-3.1) and complete course of antenatal steroids (aOR: 1.6, 95% CI: 1.1-2.2) were associated with intact survival. African American infants had a similar incidence of early HRF (21.7% vs 23.3%) but lower exposure to INO (16.4% vs 21.6%). Among infants with HRF exposed to INO, intact survival (no death or NDI) was not significantly different between African American and other races (aOR: 1.5, 95% CI: 0.6-3.6). The authors concluded that early HRF in infants ≤ 26 weeks gestation is associated with high mortality and NDI at 18 to 26 months and that use of INO did not decrease mortality or NDI.

Askie et al. (2018) conducted an individual participant data meta-analysis of three randomized controlled trials to assess whether INO improved survival without bronchopulmonary dysplasia (BPD) in preterm African American infants. Data was available for 1240 preterm infants. Studies included infants at <30 weeks to <34 weeks postmenstrual age (PMA) on greater than five ppm of INO for at least seven days; and a minimum of 15% of enrolled infants or at least 10 infants in

each treatment arm were of African American race. The intervention groups (n=628, including 202 African American infants) received INO at 10 ppm or 20 ppm for 12-24, 48-96, or 72-96 hours, with varied weaning protocols. The control infants (n=612, including 226 African American infants) received inhaled placebo treatment. The primary endpoint was a composite outcome of death or BPD, defined as requiring respiratory support or supplemental oxygen at 36 weeks PMA. Compared with infants of other races, African American infants had a significant reduction in the composite outcome of death or BPD with INO treatment: 49% in the INO groups compared with 63% in the control infants (relative risk [RR], 0.77; 95% confidence interval [CI], 0.65-0.91; p=0.003). There was no significant difference in death or BPD by race in the placebo groups. There was a significant difference between races (p=0.023) in the effect of INO treatment on the incidence of BPD in surviving infants, with the greatest effect noted in African American infants (p=0.005). There was no significant difference between racial groups for death at any time, death at discharge, or death at 36 weeks PMA. For all races, the composite outcome of death or BPD was reduced in infants treated with INO (58%) versus placebo (65%; RR, 0.90; 95% CI, 0.82-0.98; p=0.018). However there was no difference in death at any time point between the treatment groups. Limitations of the study included the age of included studies, which may not reflect more recent advances in neonatal intensive care; variations in INO protocol and dosage; variation in age inclusion criteria; the assignment of race based on maternal self-report without consideration of paternal race/ethnicity; the inclusion of few infants of other racial backgrounds and insufficient power to examine the efficacy of INO in these other racial groups; the studies were not designed to evaluate the relationship between race and response to INO therapy; and the lack of longer-term data.

Carey et al. (2018) reported on a cohort study that examined inhaled nitric oxide (INO) in extremely premature neonates with respiratory distress syndrome (RDS). The study included singletons who required mechanical ventilation for treatment of RDS and excluded those with anomalies. The primary outcome was death before discharge. Through a sequential risk set approach, each patient who received INO during the first 7 days of life (case patient) was matched by using propensity scores to a patient who had not received INO at a chronological age before the case patient's INO initiation age (defined as the index age for the matched pair). The association between INO status and in-hospital mortality was evaluated in a Cox proportional hazards regression model by using age as the time scale with patients entering the risk set at their respective index age. The study sample included 37,909 neonates, of which 993 (2.6%) received INO. The two matched cohorts each contained 971 patients. The authors did not observe a significant association between INO exposure and mortality (hazard ratio, 1.08; 95% confidence interval, 0.94-1.25; p=0.29). In a subcohort analysis, there was no significant association between INO exposure and mortality among RDS patients with concomitant persistent pulmonary hypertension of the newborn (PPHN) (HR, 0.96; 95% CI, 0.81-1.13; p=0.60). The authors concluded that off-label prescription of INO is not associated with reduced in-hospital mortality among extremely premature neonates with RDS.

Ellsworth et al. (2018) reported on a cohort study to determine whether treatment with inhaled nitric oxide during the first week of life was associated with improved in-hospital survival in a cohort of extremely preterm neonates with pulmonary hypoplasia. The study used a 1-to-1 propensity score matching to reduce the imbalance of measured covariates between two treatment groups. The initial, unmatched cohort included singleton neonates who were born between 22 and 29 weeks gestation, with birth weight of 400 g or more, with pulmonary hypoplasia as a cause of their respiratory distress, remained free of major anomalies. Exposure was defined as the initiation of inhaled nitric oxide on day *t* (exposed) in days 0 to 7 of the life of a neonate. Each exposed neonate was matched 1-to-1 to a neonate who had not initiated inhaled nitric oxide on a given day. The primary outcome was mortality, defined as death prior to transfer or discharge home. Secondary outcomes were any-stage necrotizing enterocolitis, retinopathy of prematurity requiring treatment, chronic lung disease, and periventricular leukomalacia. Among

92,635 neonates in the study sample, 767 (0.8%) were identified with pulmonary hypoplasia who met all study inclusion criteria, of whom 185 (0.2%) were exposed to inhaled nitric oxide. Among 151 matched pairs of exposed and unexposed neonates, there was not a significant association between inhaled nitric oxide use and mortality (hazard ratio [HR], 0.79; 95% CI, 0.57-1.11) identified. Subgroup analyses of neonates with and without persistent pulmonary hypertension (PPHN) likewise revealed no significant association between inhaled nitric oxide use and mortality (pulmonary hypoplasia with PPHN: HR, 0.67; 95% CI, 0.45-1.01; pulmonary hypoplasia without PPHN: HR, 1.11; 95% CI, 0.61-2.02), but the authors noted that these findings may have been influenced by ascertainment bias. The authors concluded that early treatment with inhaled nitric oxide is not associated with improved survival among extremely preterm neonates with pulmonary hypoplasia and clinical trials are warranted to clarify the matter.

Barrington et al. (2017b) conducted a Cochrane review of randomized and quasi-randomized controlled trials to evaluate the effects of INO on death, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), other serious brain injury events and on adverse long-term neurodevelopmental outcomes in preterm newborn infants (less than 35 weeks gestation) with hypoxic respiratory failure. Seventeen randomized controlled trials met inclusion criteria. Due to the substantial variation in study eligibility criteria which decreases the utility of an overall analysis, the trials were grouped into the following three categories: 1) treatment during the first three days of life for impaired oxygenation; 2) routine use in preterm babies along with respiratory support; and 3) later treatment for infants at increased risk for BPD. No overall analyses were performed. Eight trials (n=958) providing early rescue treatment for infants on the basis of oxygenation criteria demonstrated no significant effect of INO on mortality or BPD. Four studies (n=1924) evaluating routine use of INO in infants with pulmonary disease reported no significant reduction in death or BPD. The three trials (n=1075) evaluating later treatment with INO based on the risk of BPD revealed no significant benefit. No clear effect of INO was found on the frequency of all grades of IVH or severe IVH. Early rescue treatment was associated with a non-significant 20% increase in severe IVH. No effect was found on the incidence of neurodevelopmental impairment. Based on the data INO does not appear to be an effective rescue therapy for the very ill preterm infant. Early routine use of INO in preterm infants with respiratory disease did not prevent serious brain injury or improve survival without BPD. Additional studies are required to determine if late use of INO is effective in preventing BPD.

Askie et al. (2011) conducted an individual-patient data (IPD) meta-analysis which involved the central collection and reanalysis of line-by-line raw data from each randomly assigned preterm infant (< 34 weeks gestational age) (n=3298) from 11 randomized controlled trials (96% of published world-wide data). The objective of the study was to determine if INO in preterm infants who received ventilatory support improved survival without morbidity, specifically without chronic lung disease (CLD) or major neurological injury and if the effects of INO differed according to patient or intervention-related factors (e.g., gestation age at birth, birth weight, oxygen index, pulmonary hypertension). The preterm infants were randomly assigned to INO or a control group. Overall, death or CLD occurred in 59% INO-treated infants compared to 61% control infants (p=0.11). Severe neurologic events occurred in 25% of infants in the INO group compared to 23% of infants in the control group (p=0.09). There were no statistically significant differences between INO- and control-treated infants for any secondary outcomes, or for the primary end points according to patient or intervention-related factors (p>0.05, each). The relative risk of treatment effect on death or CLD in the lower-starting-dose group was significantly different than in the higher-starting-dose group (>5 ppm) (p=0.02), suggesting more benefit with the higher dose. The duration of treatment had no significant impact on the effect of treatment. The trials differed in many ways including variation in the inclusion criteria which impacted the number of high-risk infants in a group, lack of blinding to treatment after allocation, and treatment regimens. However, the authors noted that due to the variations in the treatment regimens it was difficult to draw firm conclusion regarding this data. The authors concluded that the results revealed no

benefit for the routine early use of INO in preterm infants receiving respiratory support (either mechanical ventilation or continuous positive airway pressure). Within some individual subgroups there were suggestions of significant benefits but the result was likely due to selection of particular trials with the relevant information. On the basis of treatment-by-subgroup interaction tests for differences between subgroups, there was no clear evidence that INO was more or less effective for any particular subgroup of preterm patients. The results of this meta-analysis indicated that routine use of INO for treatment of respiratory failure in preterm infants could not be recommended.

Huddy et al. (2008) reported 4–5 year outcomes of 108 infants, age less than 34 weeks gestation, who had severe respiratory failure, required ventilatory support, and were age less than 28 days when INO was administered. Infants were randomized to ventilation with INO (n=55) or ventilation without INO (n=53). A satisfactory response was defined as an increase in post-ductal arterial oxygen tension (PaO₂) of more than 3 kPa [kilopascal] (22.5 millimeters of mercury) after the first 15 minutes of giving INO. Dosage began at 5 ppm, was doubled to 10 ppm and maximized at 40 ppm if no satisfactory response was achieved. No evidence of dose-response relationship was reported. Overall assessments included the following outcomes:

- eight children were classified as normal across all domains at the age of 4–5 years (five INO vs. three no INO);
- five children (three INO vs. two no INO) had impairment only;
- ten children were classified as having mild disability (six INO vs. four no INO);
- nine children had moderate disability (five INO vs. four no INO);
- six children were severely disabled (three in each group); and
- 34 of 55 INO (62%) died or were severely disabled at the last follow-up compared to 37 of 53 (70%) of the no INO group.

Of the four children unable to participate in cognitive assessment due to the severity of disability, three were in the INO group. Of the 19 INO and 15 no INO children able to participate in cognitive assessment, there were no significant differences between the two groups in mean general conceptual ability score, verbal ability scores, pictorial reasoning, spatial abilities, or non-verbal composite. There were no significant differences in neuromotor, sensory, communication, and behavior outcomes. Based on the results of this study, there were no benefits or harms to the use of INO in preterm infants.

Di Fiore et al. (2007) conducted a study to determine if INO improved airway resistance and compliance in ventilated infants (n=71) with evolving BPD. The infants, gestational age 24.3–26.7 weeks, weight 574–930 grams (g), ages 11.5–19.6, days, were randomized to either INO (n=34) or placebo gas (n=37). Pulmonary function was assessed prior to initiation of the study, one hour and 24 hours following the initiation of therapy, and weekly thereafter until the infant was extubated or switched to high-frequency ventilation. Pulmonary function measurements included expiratory resistance (R_{exp}) and compliance normalized by weight (C_{kg}). There were no significant differences in the two groups in the one hour R_{exp} and C_{kg} values (p=0.66, p=0.40, respectively) nor at the end of week one (p=0.63, p=0.29, respectively). During week one, eight placebo-treated infants were switched to high frequency ventilation and one infant expired compared to seven INO-treated infants who were switched to high frequency ventilation. At the end of two weeks, 16 placebo-treated infants and ten INO-treated infants were available for assessment. Values at the end of week two were constant from week one. Limitations of the study include the small patient population and the number of infants lost to follow-up.

Hintz et al. (2007) conducted a multicenter randomized controlled trial to evaluate the effects of INO on neurodevelopmental impairment (NDI) and mortality in infants (n=418), gestational age less than 34 weeks, weight 401–1500 g, with severe respiratory failure. NDI was defined as moderate to severe cerebral palsy (CP), bilateral blindness, or deafness, and a score less than 70 on Bayley Scales of Infant Development [BSID] II, Mental Developmental Index [MDI] or

Psychomotor Developmental Index [PDI]. Follow-up occurred at 18 to 22 months of age corrected for prematurity. The infants were randomized to receive either INO (n=210) or placebo (n=208) based upon birth weight (i.e., 401–750 g; 751–1000 g; 1001–1500 g). Of the available infants at follow-up, 91 of 101 (90%) INO-treated infants and 102 of 112 (91%) placebo-treated infants survived. There were no significant differences in the death rate or NDI of the INO group compared to the placebo group (78% vs. 73%, respectively). Compared to the placebo group, a slightly increased risk of moderate to severe CP or death was reported in INO-treated infants with a birth weight less than 1000 g (p=0.01). Limitations of the study include the number of infants lost to follow-up and the short-term follow-up.

Van Meurs et al. (2007) conducted a randomized controlled trial to determine if INO would reduce the incidence of death and bronchopulmonary dysplasia (BPD). Infants requiring mechanical ventilation for severe respiratory failure, less than 34 weeks gestation, weight greater than 1500 g, were randomized to either INO (n=14) or placebo (n=15). Five INO-treated infants and four control group infants died before discharge. There were no significant differences between the two groups in death, BPD, death and/or BPD, or NDI outcomes. The trial was terminated due to the high incidence of grade 3 or 4 intraventricular hemorrhage or periventricular leukomalacia in the INO-treated infants. Author noted limitations of the study included the small patient population and the short duration of INO administration (i.e., maximum 14 days).

A Kinsella 2006 systematic review of INO therapy in premature newborns with hypoxemic respiratory failure and PPHN summarized the results of nine randomized controlled studies. The author reported that the studies reported conflicting results and the role of INO in this population remained controversial.

Ballard et al. (2006) conducted a randomized controlled trial including 582 infants from 21 centers (Nitric Oxide for Chronic Lung Disease [No CLD] trial). The infants, gestational age 26 weeks, had a birth weight of 1250 g or less, were on mechanical ventilators, at high risk for BPD and between ages seven and 21 days. Infants were randomly assigned to INO (n=294) and non-INO (n=288) and stratified according to weight (i.e., 500–799 g and 800–1250 g). INO was initially administered at 20 ppm, and the dosage was decreased at weekly intervals until a minimum of 24 days of treatment had been administered. The goal was survival without BPD. In the study group, 43.9% survived without BPD compared to 36.8% in the control group. INO infants received supplemental oxygen for a shorter period of time and were discharged sooner. Survival without BPD was similar in both birth-weight strata. Infants treated with INO required less supplemental oxygen and were discharged sooner. INO administered between 7 and 21 days of age improved pulmonary outcomes in preterm infants at risk for BPD. The authors pointed out that this trial differed in design from other studies in that INO was not started until the seventh day, and INO was administered for a longer period of time (i.e., 24 days versus 76 hours to 14 days). They also stated that definitive recommendations for the use of INO in this population were contingent upon long-term neurodevelopmental outcomes.

Several follow-up studies have been conducted on the Ballard et al. (2006) study discussed above. Because of the known role of INO in oxidative damage and the concern that INO could potentially increase formation of reactive oxygen and nitrogen species, Ballard et al. (2008) prospectively collected blood samples from a subset of 100 infants to determine the effect of INO on plasma biomarkers of oxidative stress for premature infants. Birth weights ranged from 502–1105 g and gestational age ranged from 22.7–30.0 weeks. Infants were entered into the study between days 7 and 21. At each of the three time points (1–10 days) during exposure to study gas, there were no significant differences between control and treated infants for concentrations of plasma protein, 3-nitrotyrosine, and carbonylation. The authors noted that the blood samples were collected over a period of four years and stored for prolonged periods. Hibbs et al. (2008) reported one-year outcomes to determine if INO decreased indicators of long-term pulmonary morbidities in this

study group. There were 230 INO-treated infants and 225 control group infants available for follow-up. Following discharge from neonatal intensive care, the INO infants received significantly less bronchodilators, inhaled steroids, systemic steroids, diuretics, and supplemental oxygen. There were no significant differences in wheezing, whistling in the chest, or rehospitalizations. Walsh et al. (2010) prospectively reported the two-year neurodevelopmental and growth outcomes of this study group. There were 243 surviving INO study patients and 234 non-INO patients available for evaluation. There were no significant differences in the growth variable or the neurodevelopment impairments (i.e., moderate or severe cerebral palsy, bilateral blindness, bilateral hearing loss, or score <70 on the Bayley Scales II) in the INO group compared to the placebo group ($p=0.39$). Kilbride et al. (2019) reported on follow-up of 34 children at 7-9 years of age that included pulmonary function testing (PFT), exercise testing, and measurement of altered exhaled nitric oxide (FeNO) levels. It was noted that there were no differences in PFTs or exercise capacity between INO treated and controls. FeNO levels showed large interpatient variability but tended to be lower in the INO treated group.

Kinsella et al. (2006) conducted a multicenter randomized controlled trial ($n=793$) to evaluate the effectiveness of INO in the treatment of newborns, 34 weeks or less gestational age, requiring mechanical ventilation. Infants were randomized to the INO group ($n=398$) or to the control-placebo group ($n=395$). The groups were further stratified by weight (i.e., 500–749 g, 750–999 g, 1000–1250 g). The study group received 5 ppm INO, within 48 hours of birth, for a median of 14 days (range 0–24). Primary outcome was death or bronchopulmonary dysplasia (BPD), at 36 weeks of postmenstrual age. Overall, there were no significant differences in the outcomes between the INO group (71.6% experienced death or BPD) and the control group (75.3% experienced death or BPD). In the 1000–1250 g birth-weight group, INO reduced BPD compared to the control group, 29.8% and 59.6%, respectively. For all the subjects, the occurrence of intracranial hemorrhage, periventricular leukomalacia, ventriculomegaly, and periventricular leukomalacia alone was reduced. INO infants had a lower incidence of periventricular leukomalacia than the control group infants. The largest reduction of periventricular leukomalacia or intracranial hemorrhage was seen in the INO 750–999 g subgroup and, overall, the INO group experienced fewer incidences of ventriculomegaly (5.2% compared to 8.9%). In the overall population, INO reduced the risk of brain injury, but it did not reduce the risk of BPD in 500–1250 g infants.

A meta-analysis by Hoehn et al. (2006) of INO in the treatment of severe hypoxemic respiratory failure in preterm infants was conducted. The analysis incorporated five randomized controlled trials, which included 808 infants age less than 34 weeks gestation. As a result of their study, the authors concluded that there was no significant difference in the rate of major intracranial hemorrhage and mortality rate in infants treated with INO. It was also noted that INO significantly reduced the incidence of chronic lung disease (CLD) and mortality of infants with CLD. However, the authors stated that the data from these studies were preliminary and should be regarded cautiously.

Van Meurs (2005) reviewed the results of five randomized clinical trials of preterm infants with respiratory distress syndrome who were treated with INO. One trial demonstrated improvement with the use of INO, but the other studies showed no improvement. Other authors have noted discrepancies among outcomes and stated that they may be attributed to variations in the severity of illness, underlying conditions, composition of the study population, and single-center versus multicenter.

Van Meurs et al. (2005) conducted a randomized clinical trial on the use of INO in premature infants with severe respiratory distress. The study included 42 neonates < 34 weeks gestation with respiratory distress who had received one dose of surfactant at least four hours prior to meeting inclusion criteria. Subjects were randomly assigned to the simulated gas flow control group ($n=21$) or to the INO group ($n=21$). The authors reported that there was no difference in

the outcomes between the two groups. INO did not reduce the incidence of death or of bronchopulmonary dysplasia.

A randomized study was conducted by Hamon et al. (2005) "to assess the oxidative balance in premature infants who were exposed to low dose INO and the relationship with their clinical outcome on day 28 of life." The study included 274 infants, < 32 weeks gestation, randomly assigned to receive 5 ppm INO. The results of the study group were compared to a nonhypoxemic infant group as a reference. They reported that INO seemed to be clinically beneficial for up to 28 days of life.

Acute Respiratory Distress Syndrome (ARDS): ARDS, or respiratory distress syndrome (RDS), is the acute onset of pulmonary edema in the absence of volume overload or depressed left ventricular function. ARDS, found in children and adults, occurs as a result of an insult or injury involving damage to the alveolar epithelium and vascular endothelium. The injury results in an accumulation of fluid, disrupts the production and function of pulmonary surfactant, and results in poor gas exchange. Treatment includes 100% oxygen administration, high levels of positive end-expiratory pressure (PEEP), high inspiratory flow rates and pharmacological therapy. It has been proposed that INO may be a treatment modality for ARDS for its pulmonary vasodilation effect in cases unresponsive to conventional therapy. ARDS is often accompanied by multisystem organ failure and patients typically do not die of primary lung injury. Outcomes of clinical trials have not demonstrated that INO has a significant effect on mortality, and it is speculated that the administration of INO may increase the risk of mortality. The routine use of INO in ARDS, including pediatric ARDS, is not supported (Emeriaud, et al., 2023; Tatham, et al., 2021).

INO has been proposed as a treatment for ARDS associated with COVID-19. It is theorized that INO may improve oxygenation, and also that it may have antiviral properties. While there are several clinical trials underway that are examining the use of INO for ARDS with COVID-19. The treatment of this condition with INO is currently unproven (Alhazzani, et al., 2020).

Wang et al. (2021) conducted a meta-analysis of 15 randomized controlled trials (RCTs) (n=1853) to evaluate the effect of inhaled nitric oxide (INO) therapy on the risk of acute kidney injury (AKI). The studies compared INO at various dosages and lengths of treatment with placebo or usual treatment, and for several indications. Four studies reported the results for treatment in the setting of acute respiratory distress syndrome (ARDS), four studies included patients undergoing cardiac surgery, three studies involved organ transplantation, and four studies reported on INO use in other diseases. The number of subjects ranged 29-385. The majority of subjects were male. Inclusion criteria for the meta-analysis included an RCT design, and data reported on the number of patients in both groups with renal dysfunction. Excluded from the analysis were retrospective studies, cohort studies, non-randomized studies, conference abstracts, and studies wherein data for renal dysfunction was not reported. The primary outcome evaluated was the risk of AKI during the period of treatment with INO. The pooled meta-analysis showed that INO treatment overall was not associated with an increased AKI risk (RR of 1.00; 95% CI 0.84–1.18; p=0.977). In a subgroup analysis, INO therapy significantly increased the risk of AKI in ARDS patients (RR 1.55, 95% CI 1.15–2.10, p=0.004); while the use of INO was associated with a reduced AKI risk in patients undergoing cardiac surgery (RR 0.80, 95% CI 0.64–0.99, p=0.037). INO use had no effect on the risk of AKI in organ transplantation recipients (RR 0.50, 95% CI 0.16–1.56, p=0.233). Limitations of the meta-analysis included variation within the studies in terms of study design, INO dosing and administration, and definitions of AKI; the inclusion of studies with mostly male patients; and only three studies included pediatric patients. The authors concluded that the effect of INO on AKI risk might be disease-specific, and further RCTs with this focus are warranted.

Gebistorf et al. (2016) conducted a Cochrane systematic review of 14 randomized controlled trials (n=1275) to evaluate the effect of INO on mortality in adults and children with ARDS. Secondary outcomes included pulmonary bleeding events, duration of mechanical ventilation and length of stay. No statistically significant effects were found on longest follow-up (one year) mortality in the INO group (250/654 deaths) (38.2%) compared to the control group (221/589 deaths) (37.5%) (moderate quality of evidence). No statistically significant effects were found on mortality at 28 days in the INO group (202/587 deaths) (34.4%) vs the control group (166/518 deaths) (32.0%). In children, there were no statistically significant effects of INO on mortality with 25/89 deaths (28.1%) in the INO group vs 34/96 deaths (35.4%) in the control group. At 24 hours following the administration of INO, a transient significant improvement was seen in arterial blood (PaO₂)/fraction of inspired oxygen (FiO₂) (moderate quality evidence), and oxygenation index (moderate quality evidence). There was no significant difference in ventilator-free days (high quality evidence). There was a statistically significant increase in renal failure in the INO groups (high quality evidence). There is insufficient evidence to support INO in any category of critically ill patients with ARDS. Inhaled nitric oxide resulted in a transient improvement in oxygenation but did not reduce mortality and may be harmful, as it seemed to increase renal impairment.

Dzierba et al. (2014) conducted a systematic review of the literature to evaluate the safety and efficacy of inhaled vasodilators focusing on INO and aerosolized epoprostenol for the treatment of ARDS or acute lung injury (ALI) in adults age 18 years or older. Nine randomized controlled trials describing the effects of INO on indexes of oxygenation and clinical outcomes met inclusion criteria. Seven studies evaluated INO for the treatment of ARDS and two studies used INO for the treatment of ALI. Conventional therapy/usual care were the most common comparator with three studies using nitrogen gas as the placebo comparator. No improvements in mortality were observed. Pooled data did not show a difference in mortality and ventilation-free days with INO. The authors noted that the optimal dose of INO to maximize oxygenation is unknown but doses of INO greater than 40 ppm did not further improve clinical outcomes and may have increased the risk of toxicity. The initial improvements seen with INO were transient with no significant differences in mortality, ventilator-free days or reduction in disease severity. Limitations of the studies included small patient populations; lack of appropriate control subjects; lack of sufficient power to detect differences in long-term outcomes; heterogeneity of dosage, timing of therapy, delivery mode of INO and heterogeneity of the definitions of ALI and ARDS in the studies. The incident of toxic effects was minimal. There is insufficient evidence to support the routine use of INO for the treatment of ARDS or ALI.

Adhikari et al. (2014) conducted a systematic review and meta-analysis of randomized controlled trials to determine if INO reduced hospital mortality in adults and children (excluding neonates) with severe acute respiratory distress syndrome (PaO₂/FiO₂ ≤ 100 mm Hg) but not in patients with mild-moderate acute respiratory distress syndrome (100 mm HG < PaO₂/FiO₂ ≤ 300 mm Hg). Nine trials (n=1142 patients) met inclusion criteria. The primary outcome was hospital mortality. Subgroup analysis compared outcomes using other PaO₂/FiO₂ thresholds. INO did not reduce mortality in patients with severe acute (p=0.93) or mild-moderate acute respiratory distress syndrome (p=0.33). The effect of INO did not differ based on the level of hypoxemia (p=0.24).

Adhikari et al. (2007) conducted a systematic review and meta-analysis of 12 randomized trials including 1237 subjects, adults and children, in which patients were treated with INO for acute lung injury and ARDS compared to subjects treated with placebo or usual treatment. Outcomes included mortality, duration of ventilation, oxygenation, pulmonary arterial pressure and adverse events. Although INO increased the ratio of partial pressure of oxygen to a fraction of inspired oxygen and decreased the oxygen index on day one, and in some cases, up to day four, there was no effect on mean pulmonary arterial pressure. There was no significant effect on the outcomes, and some patients exhibited an increased risk of developing renal dysfunction.

Angus et al. (2006) conducted a randomized controlled trial (n=378) to evaluate the effects of INO on survival and quality of life in adults with ARDS. The study also included a cost-effective analysis. Patients with an onset of ARDS within the preceding 72 hours were eligible for the study. Subjects were randomly assigned to the study group, treated with 5 ppm of INO (n=184) or to the placebo group, treated with nitrogen (n=184). Treatment was administered until oxygenation was adequate, or for up to 28 days, or death. Because the study included subjects from multiple centers across the country, survival and quality of life data were collected via telephone interviews at six months and one year following treatment. Interview tools included the Quality of Well-Being scale and interview questions. There was no significant difference in survival between the two groups at 28 days. Activities of daily living (ADL) decreased during the first 28 days (i.e., 40% below baseline), improved by the end of year one, but did not return to baseline levels. There were no significant differences in the ADLs between the study group and the control group. The Quality of Well-Being scores between the two groups were not statistically significant. The one-year survival rate for the study group was 67.3% compared to 68.3% for the control group (p=0.71). Limitations of the study as recognized by the authors included: possible selection bias, self-reported telephone interviews; and one-year follow-up.

Taylor et al. (2004) conducted a randomized controlled trial (n=385) to evaluate the effectiveness of INO at 5 ppm for the treatment of patients with acute lung injury not due to sepsis and without evidence of nonpulmonary organ system dysfunction. This study included patients from 46 hospitals. The patients, age ≥ 18 years old, had sustained a moderately severe, acute lung injury from multiple causes, and met the criteria for definition of ARDS. Patients were randomly assigned to the INO group (n=192) or to the nitrogen oxide placebo group (n=193). INO was administered for up to 28 days, until the assisted breathing device was discontinued, or until the patient died. Utilizing intent-to-treat analyses, INO did not improve the number of days alive and off assisted ventilation (p=0.97). There were no significant differences in mortality (p=0.54), days alive following a 2-hour unassisted ventilation trial (p=0.54), days alive without assisted breathing by day 28 (p=0.40), or days alive and meeting extubation criteria (p=0.89). A statistically significant increase in PaO₂ occurred during the initial 24 hours, but was resolved by 48 hours. There were no significant differences in the complications.

Bronchiolitis: INO has been proposed for the treatment of acute bronchiolitis, a common lung infection and a leading cause of hospitalizations in infants and young children. Presently, there is insufficient evidence in the published, peer-reviewed scientific literature to support the safety and efficacy of INO for this indication, and there is some evidence of harm.

A systematic review and meta-analysis by Kuitunen and Renko (2024) included three double-blinded, placebo controlled randomized controlled trials (n=166) evaluating the use INO for acute bronchiolitis in infants. The hospital length of stay was somewhat shortened in the INO group versus the placebo group -11.3 hours (h) (confidence interval [CI]: -26.8 to $+4.2$ h). Adverse event rates were similar between the groups (risk ratio [RR]: 0.94, CI: 0.70–1.26), however treatment related harms were more common the INO group (odds ratio [OR]: 3.86, CI: 1.04–14.40). Limitations included the small sample sizes, some limited data reporting, and the trials were performed by the same study group. Overall, the findings suggested that INO does not reduce hospital length of stay and may have a higher rate of treatment-associated harms in this patient population.

Cardiac Surgery: INO has been proposed for use perioperatively cardiac surgery to reduce the incidence of intra- and postoperative pulmonary hypertension and other complications. However, outcomes from controlled trials have been mixed, and have not conclusively shown that intraoperative nitric oxide or perioperative INO improves health outcomes (Yan, et al., 2024).

Schlapbach et al. (2022) conducted a randomized controlled trial (n=1371) to evaluate the effect of nitric oxide (NO) administered into the cardiopulmonary bypass (CPB) oxygenator on ventilator-free days in children undergoing surgery for congenital heart disease, versus standard care. Patients were randomized to receive NO at 20 ppm delivered into the CPB oxygenator (n=679) or to receive standard care CPB without NO (n=685). For both groups, other facets of care (e.g., perfusion management, surgery, anesthesia, postoperative inhaled nitric oxide [INO] use, ventilator weaning) were at the discretion of the treating physician. Children under two years old undergoing open congenital heart disease surgery with CPB were included in the study. Excluded were children with persistently elevated pulmonary vascular resistance; chronic ventilator dependency; severe preoperative shock states/sepsis; acute respiratory distress syndrome; methemoglobinemia; and children post-cardiac arrest on extracorporeal life support. The primary outcome was the number of ventilator-free days from the start of CPB until day 28. Other outcome measures included a composite of low cardiac output syndrome; extracorporeal life support; death; length of stay in the intensive care unit (ICU) and hospital; and postoperative troponin levels. Ultimately 1364 children underwent surgery with CPB. NO was delivered into the CPB oxygenator for 100% of the bypass time in the NO group and was not used in the standard care group. INO was used intraoperatively in 6.6% of the NO group and 6% of the standard care group. At day 28, there was no significant between-group difference in the number of ventilator-free days, with a median of 26.6 days in the NO group and 26.4 days in the standard care group (adjusted estimate of absolute difference, -0.01 days [95% confidence interval [CI], -0.25 to 0.22]; p=0.92). One hundred fifty-three patients (22.5%) in the NO group and 143 (20.9%) in the standard care group developed low cardiac output syndrome and/or received postoperative extracorporeal life support within 48 hours after initiation of CPB, or died within 28 days after initiation of bypass (adjusted odds ratio [OR], 1.12 [95% CI, 0.85 to 1.47]). The duration of ICU and hospital lengths of stay and postoperative troponin levels were not significantly different between the groups. Adverse events occurred in 75 patients (11.1%) in the NO group and 72 patients (10.5%) in the standard care group (adjusted OR, 1.07 [95% CI, 0.75 to 1.55]). Limitations of the study included a lack of blinding in the perfusionist; the use of INO treatment in some patients in both treatment groups; varied ventilator weaning or extubation readiness assessment procedures; and lack of long-term follow up.

Sardo et al. (2018) conducted a meta-analysis of randomized controlled trials (RCTs) to investigate the efficacy and safety of perioperative administration of nitric oxide in cardiac surgery. The study included 18 RCTs comprising 958 patients. The primary outcome was intensive care unit (ICU) stay, and secondary outcomes were mortality, duration of mechanical ventilation, and reduction of mean pulmonary artery pressure. The authors calculated the pooled odds ratio (OR) and the mean difference (MD) with random-effects model. Quantitative synthesis of data demonstrated a clinically negligible reduction in the length of ICU stay (MD -0.38 days, confidence interval CI [-0.65 to -0.11]; p=0.005) and mechanical ventilation duration (MD -4.81 hours, CI [-7.79 to -1.83]; p=0.002) compared with all control interventions with no benefit on mortality. The authors concluded that perioperative delivery of inhaled nitric oxide resulted to be of no or minimal benefit in patients with pulmonary hypertension undergoing cardiac surgery and that large, randomized trials are needed to further assess the effect on major clinical outcomes and cost-effectiveness.

Chronic Lung Disease (CLD): CLD or bronchopulmonary dysplasia (BPD) is defined as the “continuing need in preterm infants for supplemental inspired oxygen at 36 weeks postconceptional age” (Clark, et al., 2000). Causes of CLD include low birth weight, inflammation, mechanical distortion of the lung, and oxidative injury. INO is proposed as a treatment option due to its anti-inflammatory effect and its ability to reduce neutrophil accumulation, improve ventilation-perfusion matching, and reduce pulmonary hypertension. There is insufficient evidence to support INO for the treatment of CLD or BPD (Marks and Schreiber; 2008; Truog, 2005; Clark, et al., 2000).

Kinsella et al. (2014) conducted a multicenter, randomized controlled trial (n=124) to assess the safety and efficacy of INO (10 ppm) vs. placebo gas for the treatment of BPD in premature infants who required noninvasive supplemental oxygen within the first 72 hours after birth. The authors wanted to determine if the use of early, noninvasive INO (nasal CPAP or nasal cannula) would reduce the need for intubation, mechanical ventilation and the risk for BPD. Prior to randomization, the newborns were stratified into three different birth weight groups (500-749 g, 750-999 g, 1000-1250 g) until 30 weeks postmenstrual age. There were no differences between the INO vs. placebo in any group regarding the incidence of death (p=1.0), BPD (p=0.86), death/BPD (p=0.85), the need for mechanical ventilation (p=0.89), duration of ventilation (p=0.27) or safety outcomes including severe intracranial hemorrhage (p=0.68), necrotizing enterocolitis (p=0.23), and retinopathy of prematurity requiring treatment (p=1.00). The clinical course was not altered with the use of INO in any group nor between groups.

Mercier et al. (2010) conducted the European Union Nitric Oxide (EUNO) multicenter (n=36) randomized controlled trial to investigate the potential of INO (n=399) compared to placebo (n=401) in reducing the incidence of bronchopulmonary dysplasia (BPD) in preterm infants. Inclusion criteria included: gestation age at birth of 24–28 weeks plus six days (inclusive), a weight of at least 500 grams, and required surfactant or continuous positive airway pressure within 24 hours of birth. The primary endpoint was survival without BPD at 36 weeks postmenstrual age. Secondary endpoints included survival without substantial brain injury (i.e., grade 3 or 4 intraventricular hemorrhage; periventricular hemorrhage or periventricular leukomalacia as seen on ultrasound of the head). Mean duration of therapy was 16.3 ± 3.5 days in the INO group and 16.4 ± 6.5 days in the placebo group. There were no statistically significant differences between the two groups in the primary or secondary outcomes at days seven, 14 and 21. There were no significant differences in adverse events. INO as a preventative strategy in this patient population was unsuccessful.

Durrmeyer et al. (2013) conducted a follow-up of the above European Union Nitric Oxide (EUNO) randomized controlled trial (Mercier, et al., 2010) to evaluate neurodevelopmental outcomes at age two years (n=514). A total of 244 out of 363 INO treated infants and 270 of 374 placebo-treated infants were alive for assessment. The study groups included preterm infants born at 14–28 weeks gestation with moderate respiratory failure who received 5 ppm of INO or placebo for 7 to 21 days. There was no significant difference in the mean (SD) cognitive composite scores (Bayley Scales of Infant and Toddler Development, third edition) between the two groups (p=0.11). There were no significant differences in the frequency of cerebral palsy (p=0.89), seizure disorders (p=0.47), hearing impairment (p=0.45), vision deficits (p=0.09), hospitalizations in past year (p=1.0), home oxygen therapy (p=0.10), or growth (weight, length, head circumference; p=0.61, .086, 0.16, respectively) between the groups. At the two year-follow-up, INO started 24 hours after birth for a median of 20 days did not affect neurodevelopmental or other health outcomes for this preterm infant population.

Greenough et al. (2020) conducted a seven year follow-up of the above European Union Nitric Oxide (EUNO) randomized controlled trial (Mercier, et al., 2010) with the aim to determine the long-term effects of INO. A seven-year follow-up was undertaken of infants entered into the multicenter, double-blind, randomized, placebo-controlled trial of INO for prevention of BPD in premature infants born between 24 and 28 weeks plus six days of gestation. At seven years, survival and hospital admissions since the two-year follow-up, home oxygen therapy in the past year, therapies used in the previous month, and growth assessments were evaluated. Questionnaires were used to compare general health, well-being, and quality of life. A total of 305 children were assessed. No deaths were reported. Rates of hospitalization for respiratory problems (6.6 vs. 10.5%, INO and placebo group, respectively) and use of respiratory medications (6.6 vs. 9.2%) were similar. Two patients who received INO and one who received placebo had received

home oxygen therapy. There were no significant differences in any questionnaire-documented health outcomes. The authors concluded that INO for prevention of BPD in very premature infants with respiratory distress did not result in long-term benefits or adverse long-term sequelae and that in the light of current evidence, routine use of INO cannot be recommended for prevention of BPD in preterm infants.

Schreiber et al. (2003) conducted a randomized controlled trial (n=207) to determine if INO would decrease the incidence of CLD and death in infants less than 34 weeks gestation with respiratory distress syndrome who were treated with mechanical ventilation. Gestational age in the INO group was 27.4 ± 2.5 weeks with a birth weight of 1017 ± 369 g and 27.0 ± 2.8 weeks in the control group with a birth weight of $949 \text{ g} \pm 387$ g. Infants in the INO group were treated with 10 ppm on day one, followed by 5 ppm for six days. In addition, infants in each group were randomized to receive intermittent mandatory or high-frequency oscillatory ventilation. In the INO group, 51 infants had CLD or died (48.6%) compared to 65 infants (63.7%) in the placebo group. There were no significant differences between the groups in the overall incidence of intraventricular hemorrhage and periventricular leukomalacia, but the incidence was less severe in the INO group. Analysis of the data according to the mode of ventilation showed a significant decrease in the risk of chronic lung disease and death in the INO group and intermittent mandatory ventilation. However, the authors noted that because the study did not have sufficient power to detect a significant interaction, conclusions could not be drawn regarding the question of whether the benefit of inhaled nitric oxide is restricted to infants receiving intermittent mandatory ventilation. The beneficial effect of INO on CLD or death and long-term neurologic outcomes may have been amplified by the high rate of CLD in the control group (63.7%) and more mature neonates in the INO group.

Heart and Lung Transplantation (Adults): INO has been proposed for use in heart and lung transplantations in adult patients but there is insufficient evidence to support its efficacy. In a randomized controlled trial (n=20), Botha et al. (2007) evaluated the ability of INO to reduce neutrophil infiltration and primary graft dysfunction when administered from the onset of ventilation following lung transplantation. The outcomes demonstrated no significant effect following INO therapy. Perrin et al. (2006) conducted a randomized controlled trial to determine if INO would be effective in the treatment of pulmonary edema following lung transplantation (n=30) and concluded that INO had no effect on this population.

George et al. (2006) conducted a prospective review of 376 adult patients with pulmonary and right ventricular failure who were undergoing orthotopic heart transplantation (OHT) (n=67), orthotopic lung transplantation (OLT) (n=45), cardiac surgery (105), ventricular assist device (VAD) placement (n=66), and patients who experienced hypoxemia in other surgeries (n=34) and some medical patients (n=59) who received INO. The overall mortality was highest among medical patients and lowest after OHT and OLT. Although mortality in the VAD group was not significantly different than the cardiac surgery group, only five of the 66 cardiac patients required VAD. INO may have allowed avoidance of VAD. However, additional studies are needed to validate the outcomes of this study.

Liver Transplantation (Adults): Lang et al. (2014) conducted a two-center randomized controlled trial to assess the effectiveness of INO vs. placebo for enhancing allograft function in the immediate post-operative period and reducing longer term complications in 40 liver transplant patients. Subjects were excluded if age was less than 19 years, diagnosed with hepatopulmonary syndrome and/or allograft was being used for split liver transplantation. Patients were randomly assigned to receive 80 ppm of INO or placebo (nitrogen) which was administered until one hour post-reperfusion. Favorable changes in aminotransferase (AST) were significantly different in the INO vs. placebo group, with no treatment effect being noted for alanine transaminase (ALT), aspartate alkaline phosphatase (AP) or bilirubin. Significantly reduced complications were reported

in the INO group at nine months ($p=0.0062$). INO also increased the concentrations of nitrate ($p=0.001$), nitrite ($p=0.001$) and nitrosylhemoglobin ($p=0.001$). Significant increases in liver injury occurred post-reperfusion in both groups. There were no significant differences between the groups in intensive care and hospital length of stay, or post-operative hepatobiliary complications within the first nine months post-transplantation. There were no reported adverse events due to INO administration. Limitations of the study included the small patient population and reported significant differences in patient and surgery demographics between the two centers. The authors noted that definitive conclusions regarding the use of INO as a preemptive strategy to reduce ischemia-reperfusion injury (IRI) in liver transplantation were not possible based on this study.

Left Ventricular Assist Device (LVAD): INO has been proposed to be of benefit in the intraoperative management of patients in the setting of right ventricular dysfunction after LVAD insertion. However, data supporting favorable clinical outcomes are lacking. Potapov et al. (2011) conducted a multicenter randomized controlled trial ($n=150$) to study the safety and efficacy of INO on post-operative outcomes following placement of a left ventricular assist device (LVAD). Patients received either 40 ppm INO ($n=73$) or nitrogen placebo ($n=77$) initiated at least five minutes prior to the first weaning attempt from cardiopulmonary bypass (CPB), and therapy was continued until the patient was extubated, reached a study end point, or was treated for 48 hours. For ethical reasons, patients had the option to cross over to open-label INO immediately if they failed to wean at least once from CPB due to hemodynamic failure, still required pulmonary vasodilator support at 48 hours, or met predefined right ventricular dysfunction (RVD) criteria. Four INO patients and nine placebo patients did not undergo treatment and 15 INO patients and 20 placebo patients crossed over to open-label INO. Eighteen patients crossed over before RVD criteria were met. Although there was a trend for better outcomes in the INO group, there were no significant differences in the INO- and placebo-treated patients who met RVD criteria ($p=0.330$), spent time on mechanical ventilation ($p=0.077$), or required a right ventricular assist device (RVAD) ($p=0.468$). There were also no significant differences in the intensive care unit length of stay, hospital length of stay, 28-day mortality rates and adverse events. INO did not improve outcomes in this patient population.

Kukucka et al. (2011) conducted a randomized controlled trial to evaluate the acute effect of LVAD on right ventricular geometry and function and pulmonary circulation, as well as the effects of INO ($n=24$) compared to placebo ($n=23$). The study included elective patients without acute decompensation for chronic heart failure but with preoperative increased pulmonary vascular resistance. Following LVAD implantation, a significant decrease was seen in pulmonary capillary wedge pressure ($p<0.01$) and mean pulmonary artery pressure ($p<0.01$) in both groups with no significant difference between the INO and placebo groups. Significant improvements were also seen on transesophageal echocardiography of right ventricular geometry and function in both groups, but with no significant difference between the groups. Three INO patients and one placebo patient developed right ventricular failure due to different clinical problems. INO added no measurable effect on right ventricular geometry and function.

Acute Pulmonary Embolism (PE): Acute PE is typically a complication secondary to migration of a deep venous clot or thrombi to the lungs and is associated with considerable morbidity and mortality. Because treatment options are limited, INO has been proposed as a therapeutic option for these patients (Bhat, et al., 2015).

Kline et al. (2019) conducted a randomized, placebo-controlled, double blind trial to test the hypothesis that adjunctive inhaled NO would improve right ventricular (RV) function and viability in acute PE. Eligible patients had acute PE without systemic arterial hypotension but had RV dysfunction and a treatment plan of standard anticoagulation. Subjects received either oxygen plus 50 parts per million nitrogen (placebo) or oxygen plus 50 ppm NO for 24 h. The primary composite endpoint required a normal RV on echocardiography and a plasma troponin T

concentration <14 pg/mL. The secondary endpoint required a blood brain natriuretic peptide concentration <90 pg/mL and a Borg dyspnea score ≤ 2 . The sample size of $n=76$ tested if 30% more patients treated with NO would achieve the primary endpoint with 80% power and $\alpha = 5\%$. Seventy-eight patients were randomized and after two withdrawals, 38 were treated per protocol in each group. At 24 h, 5/38 (13%) of patients treated with placebo and 9/38 (24%) of patients treated with NO reached the primary endpoint ($p=0.375$). The secondary endpoint was reached in 34% with placebo and 13% of the NO ($p=0.11$). In a pre-planned post-hoc analysis, it was noted how many patients with RV hypokinesia or dilation at enrollment resolved these abnormalities; 29% more patients treated with NO resolved both abnormalities at 24 h ($p=0.010$, Cochrane's Q test). The authors concluded that compared with placebo, 24 hours of nasally inhaled NO did not increase the proportion of patients with intermediate-high risk PE who normalized their RV function, circulating troponin T or BNP concentrations after 24 hours of treatment and the secondary analysis suggests that inhaled NO may increase likelihood of resolving echocardiographically-observed RV hypokinesia and dilation.

Bhat et al. (2015) conducted a systematic review of the literature and reported that no large randomized controlled trials comparing INO to placebo for the treatment of PE have been reported. Studies are primarily in the form of case reports and case series with small patient populations ($n=8$). There is insufficient evidence to support INO for the treatment of PE.

Sickle Cell Disease: INO has been proposed for the treatment of acute chest syndrome (ACS) and pain associated with vaso-occlusive crisis in patients with sickle cell disease. However, evidence in the published peer-reviewed scientific literature has not demonstrated that INO reduces the duration of sickle cell pain crisis, narcotic use, pain scores, the development of ACS, rate of ACS treatment failure, or the need for transfusion (Machado and Gladwin, 2022).

Aboursheid et al. (2022) conducted a Cochrane review to capture the available body of evidence evaluating the efficacy and safety of the use of inhaled nitric oxide in treating pain crises in people with sickle cell disease. The selection criteria included randomized and quasi-randomized trials comparing inhaled nitric oxide with placebo, or standardized way of treatment of pain crises in people with sickle cell disease. The review included three studies (188 participants) that compared inhaled nitric oxide (80 ppm) to placebo (room air) for four hours; one trial continued administering nitric oxide (40 ppm) for a further four hours. This extended trial had an overall low risk of bias; however, in the remaining two trials we had concerns about the risk of bias from the small sample size and additionally a high risk of bias due to financial conflicts of interest in one of these smaller trials. The time to pain resolution was only reported in one trial (150 participants), showing there may be little or no difference between the two groups: with inhaled nitric oxide median 73.0 hours (95% confidence interval (CI) 46.0 to 91.0) and with placebo median 65.5 hours (95% CI 48.1 to 84.0) (low-quality evidence). No trial reported on the duration of the initial pain crisis. Only one large trial reported on the frequency of pain crises in the follow-up period and found there may be little or no difference between the inhaled nitric oxide and placebo groups for a return to the ED, risk ratio 0.73 (95% CI 0.31 to 1.71) or for re-hospitalization, risk ratio 0.53 (95% CI 0.25 to 1.11) (150 participants; low-quality evidence). There may be little or no difference between treatment and placebo in terms of reduction in pain score at any time point up to eight hours (150 participants). The two smaller trials reported a beneficial effect of inhaled nitric oxide in reducing the visual analogue pain score after four hours of the intervention, but these trials were small and limited compared to the first trial. The authors concluded that the available trials did not provide sufficient evidence to determine the effects of using inhaled nitric oxide to treat pain (vaso-occlusive) crises in people with sickle cell disease and that large-scale, long-term trials are needed to provide more robust data in this area.

Gladwin et al. (2011) conducted a prospective, multicenter ($n=11$), double-blind, randomized controlled trial to compare the outcomes of INO ($n=75$) to inhaled nitrogen placebo ($n=75$) for the

treatment of vaso-occlusive crisis (VOC) due to sickle cell disease. Time to VOC resolution, the primary outcome, was not significantly different ($p=0.87$) in the study group compared to the placebo group. There were also no statistically significant differences in median length of hospital stay ($p=0.30$), mean visual analog scale (VAS) pain scores at 24 hours ($p=0.90$), decrease in mean VAS scores over 2-hour intervals during the first eight hours of treatment ($p=0.90$), median total opioid use ($p=0.73$), or acute chest syndrome requiring transfusion ($p=0.79$). Although not statistically significant, the number of rehospitalizations within thirty days was higher in the placebo group. INO recipients had significantly higher nitrate levels in plasma ($p=0.03$) and levels of methemoglobin in the venous blood compared to placebo ($p=0.001$), but the levels were not toxic. INO did not improve time to crisis resolution.

Professional Societies/Organizations

American Academy of Pediatrics (AAP): In the 2014 clinical report on the use of inhaled nitric oxide in preterm infants, AAP stated that based on randomized controlled trials, traditional meta-analyses, and an individualized patient data meta-analysis study, neither rescue nor routine use of INO improves survival in preterm infants with respiratory failure. The AAP also stated that the evidence does not support INO for the purpose of preventing or improving bronchopulmonary dysplasia (BPD), severe intraventricular hemorrhage, or other neonatal morbidities. The results of the one study that suggested that 20 ppm of INO beginning in the second postnatal week may provide a small reduction in the rate of BPD needs to be confirmed by other trials. AAP concluded that the data is limited and inconsistent regarding the effects of INO on pulmonary outcomes in preterm infants in early childhood.

The AAP Committee on Fetus and Newborn (2000; reaffirmed 2010) recommendations for INO for the treatment of neonates born at or near term with hypoxic respiratory failure included the following:

- Infants with progressive hypoxic respiratory failure should be cared for in centers with the expertise and experience to provide multiple modes of ventilatory support and rescue therapies or be transferred in a timely manner to such an institution.
- INO therapy should be given using the indications, dosing, administration, and monitoring guidelines outlined on the product label. An echocardiogram to rule out congenital heart disease is recommended. Center-specific criteria for treatment failure should be developed to facilitate timely consideration of alternative therapies.
- INO therapy should be directed by physicians qualified by education and experience in its use and offered only at centers that are qualified to provide multisystem support, generally including on-site ECMO capability.
- Generally, INO should be initiated in centers with ECMO capability. If INO is offered by a center without ECMO capability, for geographic or other compelling reasons, mutually acceptable treatment failure criteria and mechanisms for timely transfer of infants to a collaborating ECMO center should be established prospectively. Transfer must be accomplished without interruption of INO therapy.
- Centers that provide INO therapy should provide comprehensive long-term medical and neurodevelopmental follow-up.
- Centers that provide INO therapy should establish prospective data collection for treatment time course, toxic effects, treatment failure, use of alternative therapies, and outcomes.
- Administration of INO for indications other than those approved by the FDA or in other neonatal populations, including compassionate use, remains experimental. As such, INO should be administered according to a formal protocol that has been approved by the FDA and the institutional review board and with informed parental consent.

American Association for Respiratory Care (AARC): Based on a systematic review of the literature, the AARC (2010) published evidence-based clinical practice guidelines for INO for neonates with acute hypoxic respiratory failure. The recommendations included:

1. "A trial of INO is recommended in newborns (≥ 34 wk gestation, < 14 d [days] of age) with $\text{PaO}_2 < 100$ mm Hg [millimeters of mercury] on $\text{FIO}_2 1.0$ and/or an oxygenation index (OI) > 25 .
2. It is recommended that INO therapy be instituted early in the disease course, which potentially reduces the length of mechanical ventilation, oxygen requirement, and stay within the intensive care unit.
3. It is recommended that INO should not be used routinely in newborns with congenital diaphragmatic hernia.
4. It is suggested that INO therapy should not be used routinely in newborns with cardiac anomalies dependent on right-to-left shunts, congestive heart failure, and those with lethal congenital anomalies.
5. It is suggested that there are insufficient data to support the routine use of INO therapy in postoperative management of hypoxic term or near-term infants with congenital heart disease.
6. The recommended starting dose for INO is 20 ppm [parts per million].
7. It is recommended that response to a short trial (30–60 min) of INO should be judged by an improvement in PaO_2 or oxygenation index (OI); if there is no response, INO should be discontinued.
8. For the newborn with parenchymal lung disease, it is recommended that optimal alveolar recruitment be established prior to initiation of INO therapy.
9. For newborns with a response to INO therapy, it is recommended that the dose should be weaned to the lowest dose that maintains that response.
10. It is recommended that INO should not be discontinued until there is an appreciable clinical improvement; that the INO dose should be weaned to 1 ppm before an attempt is made to discontinue; and that the FIO_2 should be increased prior to discontinuation of INO therapy.
11. It is recommended that FDA-approved INO delivery systems should be used to assure consistent and safe gas delivery during therapy.
12. During conventional mechanical ventilation, it is suggested that the INO gas injector module should be placed on the dry side of the humidifier.
13. During conventional ventilation, it is suggested that the sampling port be placed in the inspiratory limb of the ventilator, downstream from the site of injection, no greater than 15 cm [centimeters] proximal the patient connection/interface.
14. It is suggested that the FIO_2 be measured downstream from the injection of INO into the circuit.
15. It is suggested that the patient/ventilator system be continuously monitored for changes in ventilation parameters, with adjustments to maintain desired settings during INO therapy.
16. It is suggested that the lowest effective doses of INO and O_2 be used, to avoid excessive exposure to NO, NO_2 , and methemoglobinemia.
17. It is suggested that the INO delivery system be properly purged before use to minimize inadvertent exposure to NO_2 .
18. It is suggested that the high NO_2 alarm be set at 2 ppm on the delivery system to prevent toxic gas exposure to the lungs.
19. It is suggested that methemoglobin be monitored approximately 8 hours and 24 hours after therapy initiation and daily thereafter.
20. It is suggested that the INO dose be weaned or discontinued if methemoglobin rises above 5%.
21. It is suggested that continuous pulse oximetry and hemodynamic monitoring be used to assess patient response to INO therapy.

22. It is suggested that scavenging of exhaled and unused gases during INO therapy is not necessary”.

American College of Chest Physicians (ACCP): In their evidence-based practice guidelines for the treatment of pulmonary arterial hypertension, the ACCP (2014) stated that patients with idiopathic pulmonary hypertension should undergo acute vasoreactivity testing using a short-acting agent such as IV epoprostenol, adenosine or inhaled nitric oxide. In the assessment of symptomatic pulmonary arterial hypertension, ACCP noted that a positive acute vasodilator response is defined as a fall in mean PAP of > 10 mm Hg to an mean PAP < 40 mm Hg, with an unchanged or increased cardiac output when challenged with inhaled nitric oxide, IV epoprostenol, or IV adenosine. The 2019 update of the adult guideline did not specifically address inhaled nitric oxide, but did continue to “suggest that patients with [pulmonary arterial hypertension], in the absence of contraindications, should undergo acute vasoreactivity testing using a short-acting agent at a center with experience in the performance and interpretation of vasoreactivity testing (ungraded consensus-based statement)” (Klinger, et al., 2019).

American College of Critical Care Medicine (ACCCM): In the 2017 update of ACCCM Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock, Davis et al. (2017) discussed the treatment of PPHN in the newborn. ACCCM stated, “Hyperoxygenate initially with 100% oxygen and institute metabolic alkalization (up to pH 7.50) with NaHCO₃ or tromethamine unless and until inhaled NO is available. Mild hyperventilation to produce a respiratory alkalosis can also be instituted until 100% oxygen saturation and less than 5% difference in preductal and postductal saturations are obtained. Inhaled nitric oxide should be administered as the first treatment when available.”

American Heart Association (AHA) and American Thoracic Society (ATS): AHA and ATS (Abman, et al., 2015) established a working group of clinicians and clinician-scientists in an effort to define a comprehensive set of clinical care guidelines, based on a systematic review of the literature and expert opinion, for the treatment of pulmonary hypertension (PH) in children. PH in children is defined as a resting mean pulmonary artery pressure (mPAP) >25 mm Hg beyond the first few months of life. The Societies noted that there is a lack of extensive clinical research in children and a significant paucity of multicenter, randomized controlled trials. The recommendations in the guidelines are scored based on the American College of Cardiology Foundation/AHA Clinical Practice Guideline Methodology Summit Report. The ratings include four classes and three levels of evidence. The Class of Recommendation is an estimate of the magnitude of the treatment effect, with consideration given to risks versus benefits, and the evidence and agreement that a given treatment or procedure is or is not useful or effective. The Level of Evidence is an estimate of the certainty or precision of the treatment effect.

Classes of the recommendations include:

- Class I: Benefit >>> Risk; procedure/treatment should be performed/administered
- Class IIa: Benefit >> Risk; additional studies with focused objectives needed. It is reasonable to perform procedure/administer treatment.
- Class IIb: Benefit ≥ Risk; additional studies with broad objectives needed; additional registry data would be helpful. Procedure/treatment may be considered
- Class III: No benefit: procedure/test, not helpful; treatment of no proven benefit
- Class III: Harm: procedure/test, excess cost, without benefit or harmful; treatment harmful to patients

The weight of evidence supporting each recommendation is classified as follows:

- Level A: Multiple populations evaluated. Data derived from multiple randomized clinical trials or meta-analyses

- Level B: Limited populations evaluated. Data derived from a single randomized trial or nonrandomized studies
- Level C: Very limited populations evaluated. Only consensus opinion of experts, case studies, or standard of care

The authors noted that that many more conditions are associated with PH in children than in adults, casting some doubt about the direct applicability of the adult classification system and treatment guidelines to children. Therapeutic strategies for adult pulmonary artery hypertension (PAH) have not been sufficiently studied in children to allow definition of potential toxicities or optimal dosing. Moreover, clinical research in pediatric PH suffers from a lack of age appropriate clinical end points.

The guidelines include the following recommendations regarding the use of INO:

- Persistent pulmonary hypertension (PH) in infants
 - Inhaled nitric oxide (INO) is indicated to reduce the need for extracorporeal membrane oxygenation (ECMO) support in term and near-term infants with persistent pulmonary hypertension (PPHN) of the newborn or hypoxemic respiratory failure who have an oxygenation index that exceeds 25 (Class I; Level of Evidence A)
 - INO can be beneficial for preterm infants with severe hypoxemia that is due primarily to PPHN physiology rather than parenchymal lung disease, particularly if associated with prolonged rupture of membranes and oligohydramnios (Class IIa; Level of Evidence B).
- Congenital diaphragmatic hernia (CDH) in infants
 - INO therapy can be used to improve oxygenation in infants with CDH and severe PH but should be used cautiously in subjects with suspected LV dysfunction (Class IIa; Level of Evidence B). In the discussion of this recommendation, it was noted that INO may play an important role in stabilizing patients before ECMO is initiated improving the chances that ECMO cannulation may proceed safely. However, the Societies stated that overall, there was consensus that INO should not be used routinely in CDH. Its use should be limited to patients with suprasystemic pulmonary vascular resistance (PVR) with right-to-left shunting across the oval foramen causing critical preductal hypoxemia and after optimal lung inflation and adequate left ventricular (LV) performance are established.
- Bronchopulmonary dysplasia (BPD) in infants
 - Treatment with INO can be effective for infants with established and symptomatic pulmonary hypertension (PH) (Class IIa; Level of Evidence C). AHA/ATS noted that current therapies used for PH therapy in infants with BPD generally include INO, sildenafil, endothelin receptor antagonist (ERAs), and calcium channel blockers (CCBs). INO causes selective pulmonary vasodilation and improves oxygenation in infants with established BPD. Although long-term INO therapy has been used in infants with BPD, efficacy data are not available. INO is not recommended for the prevention of BPD.
- PH crises/acute right ventricular (RV) failure in children
 - In addition to conventional postoperative care, INO and/or inhaled PGI₂ [inhaled prostacyclin] should be used as the initial therapy for pulmonary hypertensive crisis (PHCs) and failure of the right side of the heart (Class I; Level of Evidence B). According to AHA/ATS, INO has become an accepted standard for the treatment of postoperative PH at low doses to improve ventilation-perfusion matching, decrease intrapulmonary shunt fraction and in some cases, improvement in systemic arterial oxygenation. INO is commonly used to treat postoperative PH in CHD patients. A retrospective review suggested that INO may reduce mortality following repair of atrioventricular septal defects.

Global Initiative for Chronic Obstructive Lung Disease (GOLD): The 2024 update of the GOLD Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease report included a discussion regarding the administration of vasodilators in

patients with COPD. The report stated that INO can worsen gas exchange due to altered hypoxic regulation of ventilation-perfusion balance, and therefore, is contraindicated in stable COPD.

European Paediatric Pulmonary Vascular Disease Network (EPPVDN): In 2019, the EPPVDN updated their consensus statement on the diagnosis and treatment of children and young adults with pulmonary hypertension (PH). The document was endorsed by the Association for European Pediatric and Congenital Cardiology (AEPC), the European Society for Pediatric Research (ESPR), and the International Society of Heart and Lung Transplantation (ISHLT). The recommendations were graded according to the European Society of Cardiology and the American Heart Association grading system, and included the following levels of evidence and classifications (Hansmann, et al., 2019):

Classes of recommendations (COR):

- Class I: Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective (is recommended/is indicated)
- Class II: Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure
- Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy (should be considered)
- Class IIb: Usefulness/efficacy is less well established by evidence/opinion (may be considered)
- Class III: Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful (is not recommended)

Levels of Evidence (LOE)

- LOE A: Data derived from multiple randomized clinical trials or meta-analyses
- LOE B: Data derived from a single randomized clinical trial or large non-randomized studies
- LOE C: Consensus of opinion of the experts and/or small studies, retrospective studies, registries

The Network recommendations on acute pulmonary vasoreactivity testing (AVT) in the evaluation of children with PH/pulmonary vascular disease (PVD) indicated that testing should be performed using INO, and that the combination of INO with oxygen improves pulmonary hemodynamics greater than INO alone (COR I; LOE B).

The EPPVDN recommendations on the treatment of pediatric PH noted that INO is primarily used in an intensive care setting and is "useful in patients with acute pulmonary vascular crisis and/or acute exacerbation of PH in the setting of an underlying parenchymal lung disease and/or [persistent pulmonary hypertension] (PPHN)" (COR I; LOE B). When weaning from INO, rebound PH may occur that can be prevented through concomitant use of oral or IV sildenafil administration (COR I; LOE B).

The consensus statement on the treatment of acute pediatric pulmonary hypertension in the intensive care unit stated that INO may be considered for the treatment of postoperative pulmonary hypertension in mechanically ventilated patients to improve oxygenation and reduce the risk of pulmonary hypertensive crisis (COR IIb; LOE B).

Regarding persistent pulmonary hypertension (PPHN) and pulmonary hypertension associated with bronchopulmonary dysplasia (BPD)/neonatal chronic lung disease, the Network stated INO is indicated for the treatment of PPHN in mechanically ventilated term and near-term newborn infants to improve oxygenation and to reduce the need for ECMO (a) if PaO₂ is less than 100 mm Hg (while receiving 100% oxygen), or (b) if the oxygenation index exceeds 25 (COE I; LOE A).

The Network further stated that it is not well established that INO in preterm infants < 34 weeks of gestation with respiratory failure reduces the incidence of BPD (COR IIb; LOE C); and that INO may be considered in preterm infants < 34 weeks of gestation with respiratory failure and confirmed PH (COR IIb; LOE C) (Hansmann, et al., 2019).

European Society of Cardiology (ESC)/European Respiratory Society (ERS): In the 2022 updated guidelines on the diagnosis and management of pulmonary hypertension, the ESC and ERS recommended the use of inhaled nitric oxide, inhaled iloprost, or intravenous epoprostenol for performing vasoreactivity testing (Class I recommendation; Level of evidence: C*) (Humbert, et al., 2022). The guidelines were endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG).

*Class I: Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Treatment is recommended or is indicated. Level of evidence C: Consensus of opinion of the experts and/or small studies, retrospective studies, registries

Faculty of Intensive Care Medicine and Intensive Care Society Guideline Development Group: These organizations published guidelines for the management of adult patients with acute respiratory distress syndrome (ARDS). The guidelines noted a GRADE recommendation statement: "We do not suggest using iNO in patients with ARDS". (GRADE recommendation: weakly against) (Griffiths et al., 2019).

International Society for Heart and Lung Transplantation (ISHLT): In 2022, the ISHLT published a consensus statement on the management of patients with pulmonary hypertension (PH) and right heart failure undergoing surgery. Regarding intraoperative management, the authors stated "Inhaled pulmonary vasodilators (nitric oxide, epoprostenol, iloprost) are of uncertain benefit for many PH patients. Caution should be applied to their use in patients with decompensated [left ventricular] failure and PH" (McGlothlin, et al., 2022). The statement further noted that, in the postoperative setting, there may be a need to initiate a short-acting pulmonary vasodilator (including INO) for worsening PH and right ventricular dysfunction.

National Institute for Health and Care Excellence (NICE): The 2019 NICE guideline on specialist neonatal respiratory care for preterm babies stated "Do not routinely use inhaled nitric oxide for preterm babies who need respiratory support for respiratory distress syndrome (RDS), unless there are other indications such as pulmonary hypoplasia or pulmonary hypertension". The guideline noted that the use of INO for pulmonary hypoplasia or pulmonary hypertension in babies less than 34 weeks gestation is "off-label", and that the inclusion of these exceptions was based on author clinical experience, rather than on findings in the published literature.

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD	National	No Determination found	
LCD		No Determination found	

Note: Please review the current Medicare Policy for the most up-to-date information. (NCD = National Coverage Determination; LCD = Local Coverage Determination)

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Medically Necessary when used in association with the administration of inhaled nitric oxide when criteria in the applicable policy statements listed above are met:

CPT®* Codes	Description
93463	Pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed (List separately in addition to code for primary procedure)
94002	Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; hospital inpatient/observation, initial day
94003	Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; hospital inpatient/observation, each subsequent day

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

ICD-10-PCS Procedure Codes	Description
3E0F3SD	Introduction of Nitric Oxide Gas into Respiratory Tract, Percutaneous Approach
3E0F7SD	Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening
3E0F8SD	Introduction of Nitric Oxide Gas into Respiratory Tract, Via Natural or Artificial Opening Endoscopic

***Current Procedural Terminology (CPT®) ©2023 American Medical Association: Chicago, IL.**

References

1. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al.; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric Pulmonary Hypertension: Guidelines from the American Heart Association and American Thoracic Society. *Circulation*. 2015 Nov 24;132(21):2037-99. Accessed May 14, 2024. Available at URL address: <https://www.ahajournals.org/doi/full/10.1161/cir.0000000000000329>

2. Aboursheid T, Albaroudi O, Alahdab F. Inhaled nitric oxide for treating pain crises in people with sickle cell disease. *Cochrane Database Syst Rev.* 2022 Jul 8;7(7):CD011808.
3. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. *BMJ.* 2007 Apr 14;334(7597):779.
4. Adhikari NK, Dellinger RP, Lundin S, Payen D, Vallet B, Gerlach H, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis. *Crit Care Med.* 2014 Feb;42(2):404-12.
5. Agency for Healthcare Research and Quality (AHRQ). Evidence report/technology assessment number 195, Inhaled nitric oxide in preterm infants. Oct 2010. Archived. Accessed May 14, 2024. Available at URL address: <https://www.ahrq.gov/research/findings/evidence-based-reports/search.html>
6. Aikio O, Metsola J, Vuolteenaho R, Perhomaa M, Hallman M. Transient defect in nitric oxide generation after rupture of fetal membranes and responsiveness to inhaled nitric oxide in very preterm infants with hypoxic respiratory failure. *J Pediatr.* 2012 Sep;161(3):397-403.e1.
7. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundry M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med.* 2020 May;46(5):854-887.
8. Alqahtani JS, Aldhahir AM, Al Ghamdi SS, AlBahrani S, AlDraiwiesh IA, Alqarni AA, Latief K, Raya RP, Oyelade T. Inhaled Nitric Oxide for Clinical Management of COVID-19: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health.* 2022 Oct 6;19(19):12803.
9. American Academy of Pediatrics (AAP). Committee on Fetus and Newborn. Use of inhaled nitric oxide. *Pediatrics.* 2000 Aug;106(2 Pt 1):344-5. Reaffirmation Apr 2010. Accessed May 14, 2024. Available at URL address: <https://publications.aap.org/pediatrics/article-abstract/106/2/344/62822/Use-of-Inhaled-Nitric-Oxide>
10. American Academy of Pediatrics (AAP). Committee on Fetus and Newborn. Clinical report. Use of inhaled nitric oxide in preterm infants. *Pediatrics* 2014;133:1 165-170. Accessed May 14, 2024. Available at URL address: <https://publications.aap.org/pediatrics/article/133/1/164/68331/Use-of-Inhaled-Nitric-Oxide-in-Preterm-Infants>
11. American Association for Respiratory Care (AARC). Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure. 2010. Accessed May 14, 2024. Available at URL address: <https://www.aarc.org/resource/clinical-practice-guidelines/>
12. Angus DC, Clermont G, Linde-Zwirble WT, Musthafa AA, Dremsizov TT, Lidicker J, Lave JR; NO-06 Investigators. Healthcare costs and long-term outcomes after acute respiratory

- distress syndrome: A phase III trial of inhaled nitric oxide. *Crit Care Med.* 2006 Dec;34(12):2883-90.
13. Arul N, Konduri GG. Inhaled nitric oxide for preterm neonates. *Clin Perinatol.* 2009 Mar;36(1):43-61.
 14. Askie LM, Ballard RA, Cutter G, Dani C, Elbourne D, Field D, et al; Meta-Analysis of Preterm Patients on inhaled Nitric Oxide (MAPPiNO) Collaboration. Inhaled nitric oxide in preterm infants: a systematic review and individual patient data meta-analysis. *BMC Pediatr.* 2010 Mar 23;10:15.
 15. Askie LM, Ballard RA, Cutter GR, Dani C, Elbourne D, Field D, et al.; Meta-analysis of Preterm Patients on Inhaled Nitric Oxide Collaboration. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. *Pediatrics.* 2011 Oct;128(4):729-39.
 16. Askie LM, Davies LC, Schreiber MD, Hibbs AM, Ballard PL, Ballard RA. Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis. *J Pediatr.* 2018 Feb;193:34-39.e2.
 17. Austin ED, Phillips JA III, Loyd JE. Heritable Pulmonary Arterial Hypertension Overview. 2002 Jul 18 [Updated 2020 Dec 23]. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. *GeneReviews*[®] [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1485/>
 18. Ballard PL, Truog WE, Merrill JD, Gow A, Posencheg M, Golombek SG, et al. Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants. *Pediatrics.* 2008 Mar;121(3):555-61.
 19. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, et al.; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. *N Engl J Med.* 2006 Jul 27;355(4):343-53.
 20. Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. *Cochrane Database of Systematic Reviews* 2017a, Issue 1. Art. No.: CD000399.
 21. Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. *Cochrane Database of Systematic Reviews* 2017b, Issue 1. Art. No.: CD000509.
 22. Barst RJ, Agnoletti G, Fraise A, Baldassarre J, Wessel DL; NO Diagnostic Study Group. Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension. *Pediatr Cardiol.* 2010 Jul;31(5):598-606.
 23. Beyond Air[®]. LungFit[®] PH. © 2024. Accessed May 14, 2024. Available at URL address: <https://lungfitph.com>
 24. Bhat T, Neuman A, Tantary M, et al. Inhaled nitric oxide in acute pulmonary embolism: A systematic review. *Rev Cardiovasc Med.* 2015;16(1):1-8.
 25. Bizzarro M, Gross I, Barbosa FT. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. *Cochrane Database of Systematic Reviews* 2014, Issue 7. Art. No.: CD005055.

26. Bloch KD, Ichinose F, Roberts JD Jr, Zapol WM. Inhaled NO as a therapeutic agent. *Cardiovasc Res.* 2007 Jul 15;75(2):339-48.
27. Botha P, Jeyakanthan M, Rao JN, Fisher AJ, Prabhu M, Dark JH, Clark SC. Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. *J Heart Lung Transplant.* 2007 Nov;26(11):1199-205.
28. Bronicki RA, Fortenberry J, Schreiber M, Checchia PA, Anas NG. Multicenter randomized controlled trial of inhaled nitric oxide for pediatric acute respiratory distress syndrome. *J Pediatr.* 2015 Feb;166(2):365-9.
29. Buckley MS, Agarwal SK, Garcia-Orr R, Saggarr R, MacLaren R. Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults. *J Intensive Care Med.* 2021 Apr;36(4):466-476.
30. Cannon BC, Feltes TF, Fraley JK, Grifka RG, Riddle EM, Kovalchin JP. Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response. *Pediatr Cardiol.* 2005 Sep-Oct;26(5):565-9.
31. Carey WA, Weaver AL, Mara KC, Clark RH. Inhaled Nitric Oxide in Extremely Premature Neonates With Respiratory Distress Syndrome. *Pediatrics.* 2018 Feb 9. pii: e20173108.
32. Carroll CL, Backer CL, Mavroudis C, Cook K, Goodman DM. Inhaled prostacyclin following surgical repair of congenital heart disease--a pilot study. *J Card Surg.* 2005 Sep-Oct;20(5):436-9.
33. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determinations (LCDs) alphabetical index. Accessed Apr 19, 2024. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/local-coverage-proposed-lcds-alphabetical-report.aspx?proposedStatus=A&sortBy=title>
34. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs) alphabetical index. Accessed Apr 19, 2024. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/national-coverage-ncd-report.aspx?chapter=all&sortBy=title>
35. Chandrasekharan P, Lakshminrusimha S, Chowdhury D, Van Meurs K, Keszler M, Kirpalani H, et al.; NRN STEERING COMMITTEE. Early Hypoxic Respiratory Failure in Extreme Prematurity: Mortality and Neurodevelopmental Outcomes. *Pediatrics.* 2020 Oct;146(4):e20193318.
36. Chock VY, Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Kendrick DE, Stevenson DK; NICHD Neonatal Research Network. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. *Am J Perinatol.* 2009 Apr;26(4):317-22.
37. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. *N Engl J Med.* 2000 Feb 17;342(7):469-74.
38. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K, Johnston MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson WM, Rowitch

- DH. NIH Consensus Development Conference statement: inhaled nitric-oxide therapy for premature infants. *Pediatrics*. 2011 Feb;127(2):363-9.
39. Collura CA, Mara KC, Weaver AL, Clark RH, Carey WA. Outcomes of early inhaled nitric oxide use in premature African American neonates. *J Perinatol*. 2018 Dec;38(12):1657-1665.
 40. Davis AL, Carcillo JA, Aneja RK, Deymann AJ, Lin JC, Nguyen TC, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. *Crit Care Med*. 2017 Jun;45(6):1061-1093. Accessed May 14, 2024. Available at URL address: https://journals.lww.com/ccmjjournal/Fulltext/2017/06000/American_College_of_Critical_Care_Medicine.18.aspx#pdf-link
 41. Di Fiore JM, Hibbs AM, Zadell AE, Merrill JD, Eichenwald EC, Puri AR, et al. The effect of inhaled nitric oxide on pulmonary function in preterm infants. *J Perinatol*. 2007 Dec;27(12):766-71.
 42. Durrmeyer X, Hummler H, Sanchez-Luna M, Carnielli VP, Field D, Greenough A, et al.; European Union Nitric Oxide Study Group. Two-year outcomes of a randomized controlled trial of inhaled nitric oxide in premature infants. *Pediatrics*. 2013 Sep;132(3):e695-703.
 43. Dzierba AL, Abel EE, Buckley MS, Lat I. A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome. *Pharmacotherapy*. 2014 Mar;34(3):279-90.
 44. Ellsworth MA, Harris MN, Carey WA, Spitzer AR, Clark RH. Off-label use of inhaled nitric oxide after release of NIH consensus statement. *Pediatrics*. 2015 Apr;135(4):643-8.
 45. Ellsworth KR, Ellsworth MA, Weaver AL, Mara KC, Clark RH, Carey WA. Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia. *JAMA Pediatr*. 2018 May 7:e180761.
 46. Emeriaud G, López-Fernández YM, Iyer NP, Bembea MM, Agulnik A, Barbaro RP, Baudin F, Bhalla A, Brunow de Carvalho W, Carroll CL, Cheifetz IM, Chisti MJ, Cruces P, Curley MAQ, Dahmer MK, Dalton HJ, Erickson SJ, Essouri S, Fernández A, Flori HR, Grunwell JR, Jouvét P, Killien EY, Kneyber MCJ, Kudchadkar SR, Korang SK, Lee JH, Macrae DJ, Maddux A, Modesto I Alapont V, Morrow BM, Nadkarni VM, Napolitano N, Newth CJL, Pons-Odena M, Quasney MW, Rajapreyar P, Rambaud J, Randolph AG, Rimensberger P, Rowan CM, Sanchez-Pinto LN, Sapru A, Sauthier M, Shein SL, Smith LS, Steffen K, Takeuchi M, Thomas NJ, Tse SM, Valentine S, Ward S, Watson RS, Yehya N, Zimmerman JJ, Khemani RG; Second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) Group on behalf of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Executive Summary of the Second International Guidelines for the Diagnosis and Management of Pediatric Acute Respiratory Distress Syndrome (PALICC-2). *Pediatr Crit Care Med*. 2023 Feb 1;24(2):143-168.
 47. Fattouch K, Sbraga F, Sampognaro R, Bianco G, Gucciardo M, Lavallo C, et al. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. *J Cardiovasc Med (Hagerstown)*. 2006 Feb;7(2):119-23.

48. Fei Q, Pan J, Zhang F, Lin Y, Yuan T. Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis. *Crit Care Med*. 2024 Jun 1;52(6):e314-e322.
49. Fernandes JL, Sampaio RO, Brandão CM, Accorsi TA, Cardoso LF, Spina GS, et al. Comparison of inhaled nitric oxide versus oxygen on hemodynamics in patients with mitral stenosis and severe pulmonary hypertension after mitral valve surgery. *Am J Cardiol*. 2011 Apr 1;107(7):1040-5.
50. Field D, Elbourne D, Hardy P, Fenton AC, Ahluwalia J, Halliday HL, et al; INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide vs. ventilatory support without inhaled nitric oxide for infants with severe respiratory failure born at or near term: the INNOVO multicentre randomised controlled trial. *Neonatology*. 2007;91(2):73-82.
51. Finer NN, Evans N. Inhaled nitric oxide for the preterm infant: evidence versus practice. *Pediatrics*. 2015 Apr;135(4):754-6.
52. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. *Cochrane Database of Systematic Reviews* 2016, Issue 6. Art. No.: CD002787.
53. George I, Xydas S, Topkara VK, Ferdinando C, Barnwell EC, Gableman L, et al. Clinical indication for use and outcomes after inhaled nitric oxide therapy. *Ann Thorac Surg*. 2006 Dec;82(6):216:1-9.
54. Ghadimi K, Cappiello J, Cooter-Wright M, Haney JC, Reynolds JM, Bottiger BA, Klapper JA, Levy JH, Hartwig MG; INSPIRE-FLO Investigators. Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant: A Randomized Clinical Trial. *JAMA Surg*. 2022 Jan 1;157(1):e215856.
55. Ghadimi K, Cappiello JL, Wright MC, Levy JH, Bryner BS, DeVore AD, Schroder JN, Patel CB, Rajagopal S, Shah SH, Milano CA; INSPIRE-FLO Investigators. Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery. *Circulation*. 2023 Oct 24;148(17):1316-1329.
56. Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, et al; DeNOVO Investigators. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. *JAMA*. 2011 Mar 2;305(9):893-902.
57. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2024. Accessed May 14, 2024. Available at URL address: <https://goldcopd.org/2024-gold-report/>
58. González A, Bancalari A, Osorio W, Luco M, González A, Pérez H, Kattan J. Early use of combined exogenous surfactant and inhaled nitric oxide reduces treatment failure in persistent pulmonary hypertension of the newborn: a randomized controlled trial. *J Perinatol*. 2021 Jan;41(1):32-38.
59. Greenough A, Decobert F, Field D, Hallman M, Hummler HD, Jonsson B, et al. Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD): 7-year follow-up of the European Union Nitric Oxide (EUNO) trial. *J Perinat Med*. 2020 Sep 7;49(1):104-110.

60. Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. *BMJ Open Respir Res.* 2019;6(1):e000420. Published 2019 May 24.
61. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. *N Engl J Med.* 2005 Dec 22;353(25):2683-95.
62. Hamon I, Fresson J, Nicolas MB, Buchweiller MC, Franck P, Hascoet JM. Early inhaled nitric oxide improves oxidative balance in very preterm infants. *Pediatr Res.* 2005 May;57(5 Pt 1):637-43.
63. Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, Budts W, D'Alto M, Gatzoulis MA, Hasan BS, Kozlik-Feldmann R, Kumar RK, Lammers AE, Latus H, Michel-Behnke I, Miera O, Morrell NW, Pieleles G, Quandt D, Sallmon H, Schranz D, Tran-Lundmark K, Tulloh RMR, Warnecke G, Wählander H, Weber SC, Zartner P. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. *J Heart Lung Transplant.* 2019 Sep;38(9):879-901.
64. Hasan SU, Potenziano J, Konduri GG, Perez JA, Van Meurs KP, Walker MW, Yoder BA; Newborns Treated With Nitric Oxide (NEWNO) Trial Group. Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial. *JAMA Pediatr.* 2017 Nov 1;171(11):1081-1089.
65. Hermon MM, Burda G, Golej J, Boigner H, Stoll E, Kitzmüller E, et al. Methemoglobin formation in children with congenital heart disease treated with inhaled nitric oxide after cardiac surgery. *Intensive Care Med.* 2003 Mar;29(3):447-52.
66. Hibbs AM, Walsh MC, Martin RJ, Truog WE, Lorch SA, Alessandrini E, et al. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. *J Pediatr.* 2008 Oct;153(4):525-9.
67. Hilgendorff A, Apitz C, Bonnet D, Hansmann G. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart.* 2016 May;102 Suppl 2:ii49-56.
68. Hintz SR, Suttner DM, Sheehan AM, Rhine WD, Van Meurs KP. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. *Pediatrics.* 2000 Dec;106(6):1339-43.
69. Hintz SR, Van Meurs KP, Perritt R, Poole WK, Das A, Stevenson DK, et al.; NICHD Neonatal Research Network. Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide. *J Pediatr.* 2007 Jul;151(1):16-22, 22.e1-3.
70. Hoehn T, Krause MF, Buhner C. Meta-analysis of inhaled nitric oxide in premature infants: an update. *Klin Padiatr.* 2006 Mar-Apr;218(2):57-61.
71. Hoskote AU, Castle RA, Hoo AF, Lum S, Ranganathan SC, Mok QQ, Stocks J. Airway function in infants treated with inhaled nitric oxide for persistent pulmonary hypertension. *Pediatr Pulmonol.* 2008 Mar;43(3):224-35.

72. Huddy CL, Bennett CC, Hardy P, Field D, Elbourne D, Grieve R, Truesdale A, Diallo K; INNOVO Trial Collaborating Group. The INNOVO multicentre randomised controlled trial: neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for severe respiratory failure in preterm infants: follow up at 4-5 years. *Arch Dis Child Fetal Neonatal Ed.* 2008 Nov;93(6):F430-5.
73. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J.* 2022 Oct 11;43(38):3618-3731. Erratum in: *Eur Heart J.* 2023 Feb 23.
74. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. *Circulation.* 2004 Jun 29;109(25):3106-11.
75. Kaestner M, Schranz D, Warnecke G, Apitz C, Hansmann G, Miera O. Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart.* 2016 May;102 Suppl 2:ii57-66.
76. Kawakami H, Ichinose F. Inhaled nitric oxide in pediatric cardiac surgery. *Int Anesthesiol Clin.* 2004 Fall;42(4):93-100.
77. Kilbride H, Escobar H, Holmes A, Teson K, Truog W. Childhood Pulmonary Function, Exercise Capacity, and Exhaled Nitric Oxide Levels: Outcomes following Neonatal Treatment with Inhaled Nitric Oxide to Prevent Bronchopulmonary Dysplasia. *Am J Perinatol.* 2019 Mar;36(4):360-365.
78. Kim JS, McSweeney J, Lee J, Ivy D. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension. *Pediatr Crit Care Med.* 2016 Mar;17(3 Suppl 1):S89-100.
79. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. *N Engl J Med.* 2006 Jul 27;355(4):354-64.
80. Kinsella JP. Inhaled nitric oxide therapy in premature newborns. *Curr Opin Pediatr.* 2006 Apr;18(2):107-111.
81. Kinsella JP, Abman SH. Inhaled nitric oxide therapy in children. *Paediatr Respir Rev.* 2005 Sep;6(3):190-8.
82. Kinsella JP, Cutter GR, Steinhorn RH, Nelin LD, Walsh WF, Finer NN, Abman SH. Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns. *J Pediatr.* 2014 Dec;165(6):1104-1108.

83. Kinsella JP, Steinhorn RH, Krishnan US, Feinstein JA, Adata I, Austin ED, et al. Recommendations for the Use of Inhaled Nitric Oxide Therapy in Premature Newborns with Severe Pulmonary Hypertension. *J Pediatr*. 2016 Mar;170:312-4.
84. Kirbas A, Yalcin Y, Tanrikulu N, Güreer O, Isik O. Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery. *Cardiol J*. 2012;19(4):387-94.
85. Kline JA, Puskarich MA, Jones AE, et al. Inhaled nitric oxide to treat intermediate risk pulmonary embolism: A multicenter randomized controlled trial. *Nitric Oxide*. 2019;84:60-68.
86. Klinger JR. Inhaled nitric oxide in adults: Biology and indications for use. In: UpToDate, Finlay G (Ed). Jun 27, 2022. Literature review current through Mar 2024. UpToDate, Waltham, MA. Accessed Apr 19, 2024.
87. Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. *Chest*. 2019 Mar;155(3):565-586. Epub 2019 Jan 17. Erratum in: *Chest*. 2021 Jan;159(1):457.
88. Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N, Wright LL, Van Meurs K, Stork E, Kirpalani H, Peliowski A; Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. *Pediatrics*. 2004 Mar;113(3 Pt 1):559-64.
89. Krasuski RA, Devendra GP, Hart SA, Wang A, Harrison JK, Bashore TM. Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension. *J Card Fail*. 2011 Apr;17(4):265-71.
90. Kuitunen I, Renko M. Inhaled nitric oxide in acute bronchiolitis: A systematic review and meta-analysis. *Pediatr Pulmonol*. 2024 Feb;59(2):426-432.
91. Kukucka M, Potapov E, Stepanenko A, Weller K, Mladenow A, Kuppe H, Habazettl H. Acute impact of left ventricular unloading by left ventricular assist device on the right ventricle geometry and function: Effect of nitric oxide inhalation. *J Thorac Cardiovasc Surg*. 2011 Apr;141(4):1009-14.
92. Lakshminrusimha S, Keszler M. Diagnosis and management of persistent pulmonary hypertension of the newborn. In: Keszler M, Gautham KS (Eds). *Goldsmith's Assisted Ventilation of the Neonate*. 7th ed. Philadelphia, PA: Elsevier; 2022. 429-445.e4
93. Lakshminrusimha S, Kinsella JP, Krishnan US, Van Meurs K, Edwards EM, Bhatt DR, et al. Just Say No to iNO in Preterms-Really? *J Pediatr*. 2020 Mar;218:243-252.
94. Lang JD Jr, Smith AB, Brandon A, Bradley KM, Liu Y, Li W, et al. A randomized clinical trial testing the anti-inflammatory effects of preemptive inhaled nitric oxide in human liver transplantation. *PLoS One*. 2014 Feb 12;9(2):e86053.

95. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. *Chest*. 2004 Feb;125(2):580-6.
96. Linde PLC. Healthcare. Noxivent®. © 2024. Accessed May 14, 2024. Available at URL address: <https://www.lindeus.com/industries/healthcare-and-medical/noxivent>
97. Lubinsky AS, Brosnahan SB, Lehr A, Elnadoury O, Hagedorn J, Garimella B, Bender MT, Amoroso N, Artigas A, Bos LDJ, Kaufman D. Inhaled pulmonary vasodilators are not associated with improved gas exchange in mechanically ventilated patients with COVID-19: A retrospective cohort study. *J Crit Care*. 2022 Feb 15;69:153990.
98. Machado RF, Gladwin MT. Pulmonary Complications of Hematologic Diseases. In: Broaddus VC, Ernst JD, King TE, Lazarus SC, Sarmiento KF, Schnapp LM, Stapleton RD. Murray & Nadel's Textbook of Respiratory Medicine. 7th ed. Philadelphia, PA: Elsevier; 2022. Ch. 127. 1773-1787.e14.
99. Mallinckrodt Pharmaceuticals. INOmax®. © 2024. Accessed May 14, 2024. Available at URL address: <https://www.inomax.com/>
100. Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn. *Pediatr Pulmonol*. 2021 Mar;56(3):661-669.
101. Marks JD, Schreiber MD. A Randomized Clinical Trial of Inhaled Nitric Oxide Treatment in Premature Infants Reveals the Effect of Maternal Racial Identity on Efficacy. *J Clin Med*. 2023 Dec 8;12(24):7567.
102. Marks JD, Schreiber MD. Inhaled nitric oxide and neuroprotection in preterm infants. *Clin Perinatol*. 2008 Dec;35(4):793-807, viii.
103. Martin R. Respiratory distress syndrome (RDS) in preterm infants: Management. In: UpToDate, Tehrani N (Ed). Mar 4, 2024. Literature review current through Mar 2024. UpToDate, Waltham, MA. Accessed Apr 19, 2024.
104. McGlothlin DP, Granton J, Klepetko W, Beghetti M, Rosenzweig EB, Corris PA, Horn E, Kanwar MK, McRae K, Roman A, Tedford R, Badagliacca R, Bartolome S, Benza R, Caccamo M, Cogswell R, Dewachter C, Donahoe L, Fadel E, Farber HW, Feinstein J, Franco V, Frantz R, Gatzoulis M, Hwa Anne Goh C, Guazzi M, Hansmann G, Hastings S, Heerdt PM, Hemnes A, Herpain A, Hsu CH, Kerr K, Kolaitis NA, Kukreja J, Madani M, McCluskey S, McCulloch M, Moser B, Navaratnam M, Rådegran G, Reimer C, Savale L, Shlobin OA, Svetlichnaya J, Swetz K, Tashjian J, Thenappan T, Vizza CD, West S, Zuckerman W, Zuckermann A, De Marco T. ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. *J Heart Lung Transplant*. 2022 Sep;41(9):1135-1194.
105. Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D, et al.; EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. *Lancet*. 2010 Jul 31;376(9738):346-54.
106. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. *Lancet*. 2000 Oct 28;356(9240):1464-9.

107. Minai OA, Budev MM. Diagnostic strategies for suspected pulmonary arterial hypertension: a primer for the internist. *Cleve Clin J Med*. 2007 Oct;74(10):737-47.
108. Morris K, Beghetti M, Petros A, Adataia I, Bohn D. Comparison of hyperventilation and inhaled nitric oxide for pulmonary hypertension after repair of congenital heart disease. *Crit Care Med*. 2000 Aug;28(8):2974-8.
109. Muehlbacher T, Bassler D, Bryant MB. Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants. *Children (Basel)*. 2021 Apr 13;8(4):298.
110. National Heart, Lung, and Blood Institute (NHLBI). Acute Respiratory Distress Syndrome. Updated Mar 24, 2022. Accessed May 14, 2024. Available at URL address: <https://www.nhlbi.nih.gov/health/ards>
111. National Heart, Lung, and Blood Institute (NHLBI). Bronchopulmonary Dysplasia. Updated Mar 24, 2022. Accessed May 14, 2024. Available at URL address: <https://www.nhlbi.nih.gov/health/bronchopulmonary-dysplasia>
112. National Institute for Health and Care Excellence (NICE). Specialist neonatal respiratory care for babies born preterm. NG124. Apr 3, 2019. Accessed Apr 19, 2024. Available at URL address: <https://www.nice.org.uk/guidance/ng124/>
113. Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. *N Engl J Med*. 1997 Feb 27;336(9):597-604. Erratum in: *N Engl J Med* 1997 Aug 7;337(6):434.
114. Neonatal Inhaled Nitric Oxide Study Group (NINOS). Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. *The Pediatrics*. 1997 Jun;99(6):838-45.
115. Oliveira CA, Troster EJ, Pereira CR. Inhaled nitric oxide in the management of persistent pulmonary hypertension of the newborn: a meta-analysis. *Rev Hosp Clin Fac Med Sao Paulo*. 2000 Jul-Aug;55(4):145-54.
116. Ong MS, Abman S, Austin ED, Feinstein JA, Hopper RK, Krishnan US, Mullen MP, Natter MD, Raj JU, Rosenzweig EB, Mandl KD; Pediatric Pulmonary Hypertension Network and National Heart, Lung, and Blood Institute Pediatric Pulmonary Vascular Disease Outcomes Bioinformatics Clinical Coordinating Center Investigators. Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry. *J Pediatr*. 2019 Aug;211:63-71.e6.
117. Park MK, Salamat M. Pulmonary Hypertension. In: Park MK and Salamat M (Eds). *Park's Pediatric Cardiology for Practitioners*. 7th ed. Philadelphia: Elsevier; 2021. 370-377.
118. Pawar SS, Wilcox ME, van Haren FMP. Inhaled pulmonary vasodilators in severe COVID-19: Don't hold your breath. *J Crit Care*. 2022 Jan 27;69:153988.
119. Perrin G, Roch A, Michelet P, Reynaud-Gaubert M, Thomas P, Doddoli C, Auffray JP. Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content: a randomized clinical study. *Chest*. 2006 Apr;129(4):1024-30.

120. Potapov E, Meyer D, Swaminathan M, Ramsay M, El Banayosy A, Diehl C, et al. Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial. *J Heart Lung Transplant*. 2011 Aug;30(8):870-8.
121. Putnam LR, Tsao K, Morini F, Lally PA, Miller CC, Lally KP, Harting MT; Congenital Diaphragmatic Hernia Study Group. Evaluation of Variability in Inhaled Nitric Oxide Use and Pulmonary Hypertension in Patients With Congenital Diaphragmatic Hernia. *JAMA Pediatr*. 2016 Dec 1;170(12):1188-1194.
122. Robba C, Ball L, Battaglini D, Cardim D, Moncalvo E, Brunetti I; collaborators. Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. *Crit Care*. 2021 Mar 19;25(1):111.
123. Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. *N Engl J Med*. 1997 Feb 27;336(9):605-10.
124. Rosenberg AA, Lee NR, Vaver KN, Werner D, Fashaw L, Hale K, Waas N. School-age outcomes of newborns treated for persistent pulmonary hypertension. *J Perinatol*. 2010 Feb;30(2):127-34.
125. Ryan A, Tobias JD. A 5-year survey of nitric oxide use in a pediatric intensive care unit. *Am J Ther*. 2007 May-Jun;14(3):253-8.
126. Sanfilippo F, Palumbo GJ, Bignami E, Pavesi M, Ranucci M, Scolletta S, et al. Acute Respiratory Distress Syndrome in the Perioperative Period of Cardiac Surgery: Predictors, Diagnosis, Prognosis, Management Options, and Future Directions. *J Cardiothorac Vasc Anesth*. 2021 Apr 24:S1053-0770(21)00350-5.
127. Sardo S, Osawa EA, Finco G, Gomes Galas FRB, de Almeida JP, Cutuli SL, et al. Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. *J Cardiothorac Vasc Anesth*. 2018 Apr 24.
128. Schlapbach LJ, Gibbons KS, Horton SB, Johnson K, Long DA, Buckley DHF, Erickson S, Festa M, d'Udekem Y, Alphonso N, Winlaw DS, Delzoppo C, van Loon K, Jones M, Young PJ, Butt W, Schibler A; NITRIC Study Group, the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG), and the ANZICS Paediatric Study Group (PSG). Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery: The NITRIC Randomized Clinical Trial. *JAMA*. 2022 Jul 5;328(1):38-47.
129. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. *N Engl J Med*. 2003 Nov 27;349(22):2099-107.
130. Sharma R, Raizada N, Choudhary SK, Bhan A, Kumar P, Juneja R, et al. Does inhaled nitric oxide improve survival in operated congenital disease with severe pulmonary hypertension? *Indian Heart J*. 2001 Jan-Feb;53(1):48-55.

131. Sherlock LG, Wright CJ, Kinsella JP, Delaney C. Inhaled nitric oxide use in neonates: Balancing what is evidence-based and what is physiologically sound. *Nitric Oxide*. 2020 Feb 1;95:12-16.
132. Siegel MD, Siemieniuk R. Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults. In: UpToDate, Finlay G (Ed). Feb 7, 2024. Literature review current through Mar 2024. UpToDate, Waltham, MA. Accessed Apr 19, 2024.
133. Soll RF. Inhaled Nitric Oxide for Preterm Infants: What Can Change Our Practice? *Pediatrics*. 2018 Mar;141(3):e20174214.
134. Sprecher AJ, Acharya KK, Cohen SS. Persistent Pulmonary Hypertension of the Newborn (Persistent Fetal Circulation). In: Kliegman RM, St Geme JW, Blum NJ, Tasker RC, Wilson, KM, Schuh AM, Mack CL (Eds). *Nelson Textbook of Pediatrics*. 22nd ed. Philadelphia, PA: Elsevier. 2025. Ch130, 1091-1093.e1
135. Stark AR, Eichenwald EC. Persistent pulmonary hypertension of the newborn (PPHN): Management and outcome. In: UpToDate, Tehrani N (Ed). Last updated: Mar 8, 2023. Literature review current through Mar 2024. UpToDate, Waltham, MA. Accessed Apr 19, 2024.
136. Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. *Chest*. 2014 Aug;146(2):449-475. Accessed May 14, 2024. Available at URL address: [https://journal.chestnet.org/article/S0012-3692\(15\)48834-8/fulltext](https://journal.chestnet.org/article/S0012-3692(15)48834-8/fulltext)
137. Tatham KC, Ferguson ND, Zhou Q, Hand L, Austin P, Taneja R, Arroliga AC, Sanchez JF, Jimenez EJ, Staub BP, Kho ME, Domínguez-Cherit JG, Mullaly A, Arabi YM, Meade MO. Evolution of practice patterns in the management of acute respiratory distress syndrome: A secondary analysis of two successive randomized controlled trials. *J Crit Care*. 2021 Oct;65:274-281.
138. Tavare AN, Tsakok T. Does prophylactic inhaled nitric oxide reduce morbidity and mortality after lung transplantation? *Interact Cardiovasc Thorac Surg*. 2011 Nov;13(5):516-20.
139. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K Jr, Kelly KM, Smith TC, Small RJ; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. *JAMA*. 2004 Apr 7;291(13):1603-9.
140. Torgerson DG, Ballard PL, Keller RL, Oh SS, Huntsman S, Hu D, Eng C, Burchard EG, Ballard RA; TOLSURF Study Group. Ancestry and genetic associations with bronchopulmonary dysplasia in preterm infants. *Am J Physiol Lung Cell Mol Physiol*. 2018 Nov 1;315(5):L858-L869.
141. Truog WE. Chronic lung disease and randomized interventional trials: status in 2005. *NeoReviews*, 2005 Jun;1(6)6:278-88.

142. U.S. Food and Drug Administration (FDA). Drugs@FDA: FDA-Approved Drugs. Accessed Apr 19, 2024. Available at URL address:
<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
143. U.S. Food and Drug Administration (FDA). Guidance document for premarket notification submissions for nitric oxide delivery apparatus, nitric oxide analyzer and nitrogen dioxide analyzer. Jan 24, 2000. Accessed Apr 19, 2024. Available at URL address:
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-document-premarket-notification-submissions-nitric-oxide-delivery-apparatus-nitric-oxide>
144. U.S. Food and Drug Administration (FDA). INOmax (Nitric Oxide). Drug Approval package. 1999. Accessed Apr 19, 2024. Available at URL address:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20845_INOmax.cfm
145. U.S. Food and Drug Administration (FDA). Inomax (nitric oxide) for inhalation. Safety labeling changes. Aug 2009. Accessed Apr 19, 2024. Available at URL address:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020845s009lbl.pdf
146. U.S. Food and Drug Administration (FDA). Inomax (nitric oxide) for inhalation. Safety labeling changes. Mar 2013. Accessed Apr 19, 2024. Available at URL address:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020845Orig1s014.pdf
147. U.S. Food and Drug Administration (FDA). Inomax (nitric oxide) for inhalation. Safety labeling changes. Oct 2015. Accessed Apr 19, 2024. Available at URL address:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/020845Orig1s017.pdf
148. U.S. Food and Drug Administration (FDA). Inomax (nitric oxide) for inhalation. Labeling. Jan 2023. Accessed Apr 19, 2024. Available at URL address:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020845Orig1s021lbl.pdf
149. U.S. Food and Drug Administration (FDA). LungFit® PH. Premarket approval. P200044. Jun 28, 2022. Accessed Apr 19, 2024. Available at URL address:
https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200044B.pdf
150. U.S. Food and Drug Administration (FDA). Medical Device Recalls. Class 1 Device Recall GENOSYL DS. Sep 30, 2021. Accessed Apr 19, 2024. Available at URL address:
<https://www.accessdata.fda.gov/SCRIPTs/cdrh/cfdocs/cfRes/res.cfm?id=188990>
151. U.S. National Library of Medicine. ClinicalTrials.gov. Accessed May 14, 2024. Available at URL address: <https://clinicaltrials.gov>
152. Van Meurs KP. Inhaled nitric oxide therapy in the preterm infant who has respiratory distress syndrome. *NeoReviews*. 2005 June;(6)6:268-276.
153. Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. *J Perinatol*. 2007 Jun;27(6):347-52.
154. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al.; Premie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. *N Engl J Med*. 2005 Jul 7;353(1):13-22.

155. Vero Biotech. Solutions. © 2024. Accessed May 14, 2024. Available at URL address: <https://www.vero-biotech.com/solutions/>
156. Vieira F, Makoni M, Szyld E, Sekar K. The Controversy Persists: Is There a Qualification Criterion to Utilize Inhaled Nitric Oxide in Pre-term Newborns? *Front Pediatr.* 2021 Mar 31;9:631765.
157. Walsh MC, Hibbs AM, Martin CR, Cnaan A, Keller RL, Vittinghoff E, et al; NO CLD Study Group. Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide. *J Pediatr.* 2010 Apr;156(4):556-61.e1.
158. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. *Pediatrics.* 2000 Jan;105(1 Pt 1):14-20.
159. Wang J, Cong X, Miao M, Yang Y, Zhang J. Inhaled nitric oxide and acute kidney injury risk: a meta-analysis of randomized controlled trials. *Ren Fail.* 2021;43(1):281-290.
160. Wang X, Li B, Ma Y, Zhang H. Effect of NO inhalation on ECMO use rate and mortality in infants born at or near term with respiratory failure. *Medicine (Baltimore).* 2019 Oct;98(41):e17139.
161. Wang YF, Liu CQ, Gao XR, Yang CY, Shan RB, Zhuang DY, et al.; Collaborative Study Group for Neonatal Respiratory Diseases. Effects of inhaled nitric oxide in neonatal hypoxemic respiratory failure from a multicenter controlled trial. *Chin Med J (Engl).* 2011 Apr;124(8):1156-63.
162. Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. *Toxicol Sci.* 2001 Jan;59(1):5-16.
163. Yan Y, Kamenshchikov N, Zheng Z, Lei C. Inhaled nitric oxide and postoperative outcomes in cardiac surgery with cardiopulmonary bypass: A systematic review and meta-analysis. *Nitric Oxide.* 2024 May 1;146:64-74.

Revision Details

Type of Revision	Summary of Changes	Date
Annual review	<ul style="list-style-type: none"> • Revised policy statement for hypoxic respiratory failure in term or near-term infants. 	7/15/2024

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.